CINXE.COM

<!DOCTYPE html> <html class="client-nojs vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-sticky-header-enabled vector-toc-available" lang="en" dir="ltr"> <head> <meta charset="UTF-8"> <title>Nivolumab - Wikipedia</title> <script>(function(){var className="client-js vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-sticky-header-enabled vector-toc-available";var cookie=document.cookie.match(/(?:^|; )enwikimwclientpreferences=([^;]+)/);if(cookie){cookie[1].split('%2C').forEach(function(pref){className=className.replace(new RegExp('(^| )'+pref.replace(/-clientpref-\w+$|[^\w-]+/g,'')+'-clientpref-\\w+( |$)'),'$1'+pref+'$2');});}document.documentElement.className=className;}());RLCONF={"wgBreakFrames":false,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"d2602d45-6f27-40d2-9f0c-256a115d36a7","wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Nivolumab","wgTitle":"Nivolumab","wgCurRevisionId":1269019282,"wgRevisionId":1269019282,"wgArticleId":35007537,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Source attribution","Articles with short description","Short description is different from Wikidata","Use dmy dates from March 2024","Drugs with non-standard legal status","Chemicals that do not have a ChemSpider ID assigned","Articles without InChI source","Articles containing unverified chemical infoboxes","Drugs that are a monoclonal antibody","All Wikipedia articles needing clarification","Wikipedia articles needing clarification from March 2025","Wikipedia medicine articles ready to translate","Antineoplastic drugs","Drugs developed by Bristol Myers Squibb","Monoclonal antibodies for tumors","Orphan drugs","World Health Organization essential medicines"],"wgPageViewLanguage":"en","wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Nivolumab","wgRelevantArticleId":35007537,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgNoticeProject":"wikipedia","wgCiteReferencePreviewsActive":false,"wgFlaggedRevsParams":{"tags":{"status":{"levels":1}}},"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsFlags":0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFDisplayWikibaseDescriptions":{"search":true,"watchlist":true,"tagline":false,"nearby":true},"wgWMESchemaEditAttemptStepOversample":false,"wgWMEPageLength":50000,"wgEditSubmitButtonLabelPublish":true,"wgULSPosition":"interlanguage","wgULSisCompactLinksEnabled":false,"wgVector2022LanguageInHeader":true,"wgULSisLanguageSelectorEmpty":false,"wgWikibaseItemId":"Q7041828","wgCheckUserClientHintsHeadersJsApi":["brands","architecture","bitness","fullVersionList","mobile","model","platform","platformVersion"],"GEHomepageSuggestedEditsEnableTopics":true,"wgGETopicsMatchModeEnabled":false,"wgGELevelingUpEnabledForUser":false}; RLSTATE={"ext.globalCssJs.user.styles":"ready","site.styles":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.vector.search.codex.styles":"ready","skins.vector.styles":"ready","skins.vector.icons":"ready","jquery.makeCollapsible.styles":"ready","ext.wikimediamessages.styles":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","wikibase.client.init":"ready"};RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.ready","jquery.makeCollapsible","mediawiki.toc","skins.vector.js","ext.centralNotice.geoIP","ext.centralNotice.startUp","ext.gadget.ReferenceTooltips","ext.gadget.switcher","ext.urlShortener.toolbar","ext.centralauth.centralautologin","mmv.bootstrap","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.echo.centralauth","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.interface","ext.cx.eventlogging.campaigns","ext.cx.uls.quick.actions","wikibase.client.vector-2022","ext.checkUser.clientHints","ext.growthExperiments.SuggestedEditSession"];</script> <script>(RLQ=window.RLQ||[]).push(function(){mw.loader.impl(function(){return["user.options@12s5i",function($,jQuery,require,module){mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"}); }];});});</script> <link rel="stylesheet" href="/w/load.php?lang=en&modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediamessages.styles%7Cjquery.makeCollapsible.styles%7Cskins.vector.icons%2Cstyles%7Cskins.vector.search.codex.styles%7Cwikibase.client.init&only=styles&skin=vector-2022"> <script async="" src="/w/load.php?lang=en&modules=startup&only=scripts&raw=1&skin=vector-2022"></script> <meta name="ResourceLoaderDynamicStyles" content=""> <link rel="stylesheet" href="/w/load.php?lang=en&modules=site.styles&only=styles&skin=vector-2022"> <meta name="generator" content="MediaWiki 1.44.0-wmf.21"> <meta name="referrer" content="origin"> <meta name="referrer" content="origin-when-cross-origin"> <meta name="robots" content="max-image-preview:standard"> <meta name="format-detection" content="telephone=no"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/1200px-Nivolumab_5GGR.png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="1379"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/960px-Nivolumab_5GGR.png"> <meta property="og:image:width" content="800"> <meta property="og:image:height" content="919"> <meta property="og:image:width" content="640"> <meta property="og:image:height" content="736"> <meta name="viewport" content="width=1120"> <meta property="og:title" content="Nivolumab - Wikipedia"> <meta property="og:type" content="website"> <link rel="preconnect" href="//upload.wikimedia.org"> <link rel="alternate" media="only screen and (max-width: 640px)" href="//en.m.wikipedia.org/wiki/Nivolumab"> <link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Nivolumab&action=edit"> <link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"> <link rel="icon" href="/static/favicon/wikipedia.ico"> <link rel="search" type="application/opensearchdescription+xml" href="/w/rest.php/v1/search" title="Wikipedia (en)"> <link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"> <link rel="canonical" href="https://en.wikipedia.org/wiki/Nivolumab"> <link rel="license" href="https://creativecommons.org/licenses/by-sa/4.0/deed.en"> <link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&feed=atom"> <link rel="dns-prefetch" href="//meta.wikimedia.org" /> <link rel="dns-prefetch" href="login.wikimedia.org"> </head> <body class="skin--responsive skin-vector skin-vector-search-vue mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Nivolumab rootpage-Nivolumab skin-vector-2022 action-view"><a class="mw-jump-link" href="#bodyContent">Jump to content</a> <div class="vector-header-container"> <header class="vector-header mw-header"> <div class="vector-header-start"> <nav class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-dropdown" class="vector-dropdown vector-main-menu-dropdown vector-button-flush-left vector-button-flush-right" title="Main menu" > <input type="checkbox" id="vector-main-menu-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-main-menu-dropdown" class="vector-dropdown-checkbox " aria-label="Main menu" > <label id="vector-main-menu-dropdown-label" for="vector-main-menu-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-menu mw-ui-icon-wikimedia-menu"></span> <span class="vector-dropdown-label-text">Main menu</span> </label> <div class="vector-dropdown-content"> <div id="vector-main-menu-unpinned-container" class="vector-unpinned-container"> <div id="vector-main-menu" class="vector-main-menu vector-pinnable-element"> <div class="vector-pinnable-header vector-main-menu-pinnable-header vector-pinnable-header-unpinned" data-feature-name="main-menu-pinned" data-pinnable-element-id="vector-main-menu" data-pinned-container-id="vector-main-menu-pinned-container" data-unpinned-container-id="vector-main-menu-unpinned-container" > <div class="vector-pinnable-header-label">Main menu</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-main-menu.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-main-menu.unpin">hide</button> </div> <div id="p-navigation" class="vector-menu mw-portlet mw-portlet-navigation" > <div class="vector-menu-heading"> Navigation </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-mainpage-description" class="mw-list-item"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"><span>Main page</span></a></li><li id="n-contents" class="mw-list-item"><a href="/wiki/Wikipedia:Contents" title="Guides to browsing Wikipedia"><span>Contents</span></a></li><li id="n-currentevents" class="mw-list-item"><a href="/wiki/Portal:Current_events" title="Articles related to current events"><span>Current events</span></a></li><li id="n-randompage" class="mw-list-item"><a href="/wiki/Special:Random" title="Visit a randomly selected article [x]" accesskey="x"><span>Random article</span></a></li><li id="n-aboutsite" class="mw-list-item"><a href="/wiki/Wikipedia:About" title="Learn about Wikipedia and how it works"><span>About Wikipedia</span></a></li><li id="n-contactpage" class="mw-list-item"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia"><span>Contact us</span></a></li> </ul> </div> </div> <div id="p-interaction" class="vector-menu mw-portlet mw-portlet-interaction" > <div class="vector-menu-heading"> Contribute </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-help" class="mw-list-item"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia"><span>Help</span></a></li><li id="n-introduction" class="mw-list-item"><a href="/wiki/Help:Introduction" title="Learn how to edit Wikipedia"><span>Learn to edit</span></a></li><li id="n-portal" class="mw-list-item"><a href="/wiki/Wikipedia:Community_portal" title="The hub for editors"><span>Community portal</span></a></li><li id="n-recentchanges" class="mw-list-item"><a href="/wiki/Special:RecentChanges" title="A list of recent changes to Wikipedia [r]" accesskey="r"><span>Recent changes</span></a></li><li id="n-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_upload_wizard" title="Add images or other media for use on Wikipedia"><span>Upload file</span></a></li><li id="n-specialpages" class="mw-list-item"><a href="/wiki/Special:SpecialPages"><span>Special pages</span></a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> <a href="/wiki/Main_Page" class="mw-logo"> <img class="mw-logo-icon" src="/static/images/icons/wikipedia.png" alt="" aria-hidden="true" height="50" width="50"> <span class="mw-logo-container skin-invert"> <img class="mw-logo-wordmark" alt="Wikipedia" src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" style="width: 7.5em; height: 1.125em;"> <img class="mw-logo-tagline" alt="The Free Encyclopedia" src="/static/images/mobile/copyright/wikipedia-tagline-en.svg" width="117" height="13" style="width: 7.3125em; height: 0.8125em;"> </span> </a> </div> <div class="vector-header-end"> <div id="p-search" role="search" class="vector-search-box-vue vector-search-box-collapses vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box"> <a href="/wiki/Special:Search" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only search-toggle" title="Search Wikipedia [f]" accesskey="f"><span class="vector-icon mw-ui-icon-search mw-ui-icon-wikimedia-search"></span> <span>Search</span> </a> <div class="vector-typeahead-search-container"> <div class="cdx-typeahead-search cdx-typeahead-search--show-thumbnail cdx-typeahead-search--auto-expand-width"> <form action="/w/index.php" id="searchform" class="cdx-search-input cdx-search-input--has-end-button"> <div id="simpleSearch" class="cdx-search-input__input-wrapper" data-search-loc="header-moved"> <div class="cdx-text-input cdx-text-input--has-start-icon"> <input class="cdx-text-input__input" type="search" name="search" placeholder="Search Wikipedia" aria-label="Search Wikipedia" autocapitalize="sentences" title="Search Wikipedia [f]" accesskey="f" id="searchInput" > <span class="cdx-text-input__icon cdx-text-input__start-icon"></span> </div> <input type="hidden" name="title" value="Special:Search"> </div> <button class="cdx-button cdx-search-input__end-button">Search</button> </form> </div> </div> </div> <nav class="vector-user-links vector-user-links-wide" aria-label="Personal tools"> <div class="vector-user-links-main"> <div id="p-vector-user-menu-preferences" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-userpage" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-dropdown" class="vector-dropdown " title="Change the appearance of the page's font size, width, and color" > <input type="checkbox" id="vector-appearance-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-appearance-dropdown" class="vector-dropdown-checkbox " aria-label="Appearance" > <label id="vector-appearance-dropdown-label" for="vector-appearance-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-appearance mw-ui-icon-wikimedia-appearance"></span> <span class="vector-dropdown-label-text">Appearance</span> </label> <div class="vector-dropdown-content"> <div id="vector-appearance-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <div id="p-vector-user-menu-notifications" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-overflow" class="vector-menu mw-portlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="https://donate.wikimedia.org/?wmf_source=donate&wmf_medium=sidebar&wmf_campaign=en.wikipedia.org&uselang=en" class=""><span>Donate</span></a> </li> <li id="pt-createaccount-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:CreateAccount&returnto=Nivolumab" title="You are encouraged to create an account and log in; however, it is not mandatory" class=""><span>Create account</span></a> </li> <li id="pt-login-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:UserLogin&returnto=Nivolumab" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o" class=""><span>Log in</span></a> </li> </ul> </div> </div> </div> <div id="vector-user-links-dropdown" class="vector-dropdown vector-user-menu vector-button-flush-right vector-user-menu-logged-out" title="Log in and more options" > <input type="checkbox" id="vector-user-links-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-user-links-dropdown" class="vector-dropdown-checkbox " aria-label="Personal tools" > <label id="vector-user-links-dropdown-label" for="vector-user-links-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-ellipsis mw-ui-icon-wikimedia-ellipsis"></span> <span class="vector-dropdown-label-text">Personal tools</span> </label> <div class="vector-dropdown-content"> <div id="p-personal" class="vector-menu mw-portlet mw-portlet-personal user-links-collapsible-item" title="User menu" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport" class="user-links-collapsible-item mw-list-item"><a href="https://donate.wikimedia.org/?wmf_source=donate&wmf_medium=sidebar&wmf_campaign=en.wikipedia.org&uselang=en"><span>Donate</span></a></li><li id="pt-createaccount" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:CreateAccount&returnto=Nivolumab" title="You are encouraged to create an account and log in; however, it is not mandatory"><span class="vector-icon mw-ui-icon-userAdd mw-ui-icon-wikimedia-userAdd"></span> <span>Create account</span></a></li><li id="pt-login" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:UserLogin&returnto=Nivolumab" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o"><span class="vector-icon mw-ui-icon-logIn mw-ui-icon-wikimedia-logIn"></span> <span>Log in</span></a></li> </ul> </div> </div> <div id="p-user-menu-anon-editor" class="vector-menu mw-portlet mw-portlet-user-menu-anon-editor" > <div class="vector-menu-heading"> Pages for logged out editors <a href="/wiki/Help:Introduction" aria-label="Learn more about editing"><span>learn more</span></a> </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-anoncontribs" class="mw-list-item"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y"><span>Contributions</span></a></li><li id="pt-anontalk" class="mw-list-item"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n"><span>Talk</span></a></li> </ul> </div> </div> </div> </div> </nav> </div> </header> </div> <div class="mw-page-container"> <div class="mw-page-container-inner"> <div class="vector-sitenotice-container"> <div id="siteNotice"></div> </div> <div class="vector-column-start"> <div class="vector-main-menu-container"> <div id="mw-navigation"> <nav id="mw-panel" class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-pinned-container" class="vector-pinned-container"> </div> </nav> </div> </div> <div class="vector-sticky-pinned-container"> <nav id="mw-panel-toc" aria-label="Contents" data-event-name="ui.sidebar-toc" class="mw-table-of-contents-container vector-toc-landmark"> <div id="vector-toc-pinned-container" class="vector-pinned-container"> <div id="vector-toc" class="vector-toc vector-pinnable-element"> <div class="vector-pinnable-header vector-toc-pinnable-header vector-pinnable-header-pinned" data-feature-name="toc-pinned" data-pinnable-element-id="vector-toc" > <h2 class="vector-pinnable-header-label">Contents</h2> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-toc.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-toc.unpin">hide</button> </div> <ul class="vector-toc-contents" id="mw-panel-toc-list"> <li id="toc-mw-content-text" class="vector-toc-list-item vector-toc-level-1"> <a href="#" class="vector-toc-link"> <div class="vector-toc-text">(Top)</div> </a> </li> <li id="toc-Medical_uses" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Medical_uses"> <div class="vector-toc-text"> <span class="vector-toc-numb">1</span> <span>Medical uses</span> </div> </a> <ul id="toc-Medical_uses-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Side_effects" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Side_effects"> <div class="vector-toc-text"> <span class="vector-toc-numb">2</span> <span>Side effects</span> </div> </a> <button aria-controls="toc-Side_effects-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> <span class="vector-icon mw-ui-icon-wikimedia-expand"></span> <span>Toggle Side effects subsection</span> </button> <ul id="toc-Side_effects-sublist" class="vector-toc-list"> <li id="toc-Pregnancy_and_breastfeeding" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Pregnancy_and_breastfeeding"> <div class="vector-toc-text"> <span class="vector-toc-numb">2.1</span> <span>Pregnancy and breastfeeding</span> </div> </a> <ul id="toc-Pregnancy_and_breastfeeding-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-Pharmacokinetics" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Pharmacokinetics"> <div class="vector-toc-text"> <span class="vector-toc-numb">3</span> <span>Pharmacokinetics</span> </div> </a> <ul id="toc-Pharmacokinetics-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Mechanism_of_action" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Mechanism_of_action"> <div class="vector-toc-text"> <span class="vector-toc-numb">4</span> <span>Mechanism of action</span> </div> </a> <ul id="toc-Mechanism_of_action-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Physical_properties" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Physical_properties"> <div class="vector-toc-text"> <span class="vector-toc-numb">5</span> <span>Physical properties</span> </div> </a> <ul id="toc-Physical_properties-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-History" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#History"> <div class="vector-toc-text"> <span class="vector-toc-numb">6</span> <span>History</span> </div> </a> <ul id="toc-History-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Research" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Research"> <div class="vector-toc-text"> <span class="vector-toc-numb">7</span> <span>Research</span> </div> </a> <button aria-controls="toc-Research-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> <span class="vector-icon mw-ui-icon-wikimedia-expand"></span> <span>Toggle Research subsection</span> </button> <ul id="toc-Research-sublist" class="vector-toc-list"> <li id="toc-Hodgkin's_lymphoma" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Hodgkin's_lymphoma"> <div class="vector-toc-text"> <span class="vector-toc-numb">7.1</span> <span>Hodgkin's lymphoma</span> </div> </a> <ul id="toc-Hodgkin's_lymphoma-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Biomarkers" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Biomarkers"> <div class="vector-toc-text"> <span class="vector-toc-numb">7.2</span> <span>Biomarkers</span> </div> </a> <ul id="toc-Biomarkers-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Lung_cancer" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Lung_cancer"> <div class="vector-toc-text"> <span class="vector-toc-numb">7.3</span> <span>Lung cancer</span> </div> </a> <ul id="toc-Lung_cancer-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Melanoma" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Melanoma"> <div class="vector-toc-text"> <span class="vector-toc-numb">7.4</span> <span>Melanoma</span> </div> </a> <ul id="toc-Melanoma-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Urothelial_carcinoma" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Urothelial_carcinoma"> <div class="vector-toc-text"> <span class="vector-toc-numb">7.5</span> <span>Urothelial carcinoma</span> </div> </a> <ul id="toc-Urothelial_carcinoma-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-See_also" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#See_also"> <div class="vector-toc-text"> <span class="vector-toc-numb">8</span> <span>See also</span> </div> </a> <ul id="toc-See_also-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-References" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#References"> <div class="vector-toc-text"> <span class="vector-toc-numb">9</span> <span>References</span> </div> </a> <ul id="toc-References-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-External_links" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#External_links"> <div class="vector-toc-text"> <span class="vector-toc-numb">10</span> <span>External links</span> </div> </a> <ul id="toc-External_links-sublist" class="vector-toc-list"> </ul> </li> </ul> </div> </div> </nav> </div> </div> <div class="mw-content-container"> <main id="content" class="mw-body"> <header class="mw-body-header vector-page-titlebar"> <nav aria-label="Contents" class="vector-toc-landmark"> <div id="vector-page-titlebar-toc" class="vector-dropdown vector-page-titlebar-toc vector-button-flush-left" title="Table of Contents" > <input type="checkbox" id="vector-page-titlebar-toc-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-titlebar-toc" class="vector-dropdown-checkbox " aria-label="Toggle the table of contents" > <label id="vector-page-titlebar-toc-label" for="vector-page-titlebar-toc-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-listBullet mw-ui-icon-wikimedia-listBullet"></span> <span class="vector-dropdown-label-text">Toggle the table of contents</span> </label> <div class="vector-dropdown-content"> <div id="vector-page-titlebar-toc-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <h1 id="firstHeading" class="firstHeading mw-first-heading"><span class="mw-page-title-main">Nivolumab</span></h1> <div id="p-lang-btn" class="vector-dropdown mw-portlet mw-portlet-lang" > <input type="checkbox" id="p-lang-btn-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-lang-btn" class="vector-dropdown-checkbox mw-interlanguage-selector" aria-label="Go to an article in another language. Available in 17 languages" > <label id="p-lang-btn-label" for="p-lang-btn-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--action-progressive mw-portlet-lang-heading-17" aria-hidden="true" ><span class="vector-icon mw-ui-icon-language-progressive mw-ui-icon-wikimedia-language-progressive"></span> <span class="vector-dropdown-label-text">17 languages</span> </label> <div class="vector-dropdown-content"> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li class="interlanguage-link interwiki-ar mw-list-item"><a href="https://ar.wikipedia.org/wiki/%D9%86%D9%8A%D9%81%D9%88%D9%84%D9%88%D9%85%D8%A7%D8%A8" title="نيفولوماب – Arabic" lang="ar" hreflang="ar" data-title="نيفولوماب" data-language-autonym="العربية" data-language-local-name="Arabic" class="interlanguage-link-target"><span>العربية</span></a></li><li class="interlanguage-link interwiki-de mw-list-item"><a href="https://de.wikipedia.org/wiki/Nivolumab" title="Nivolumab – German" lang="de" hreflang="de" data-title="Nivolumab" data-language-autonym="Deutsch" data-language-local-name="German" class="interlanguage-link-target"><span>Deutsch</span></a></li><li class="interlanguage-link interwiki-el mw-list-item"><a href="https://el.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Greek" lang="el" hreflang="el" data-title="Nivolumab" data-language-autonym="Ελληνικά" data-language-local-name="Greek" class="interlanguage-link-target"><span>Ελληνικά</span></a></li><li class="interlanguage-link interwiki-es mw-list-item"><a href="https://es.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Spanish" lang="es" hreflang="es" data-title="Nivolumab" data-language-autonym="Español" data-language-local-name="Spanish" class="interlanguage-link-target"><span>Español</span></a></li><li class="interlanguage-link interwiki-fa mw-list-item"><a href="https://fa.wikipedia.org/wiki/%D9%86%DB%8C%D9%88%D8%A7%D9%84%DB%8C%D9%88%D9%85%D8%A8" title="نیوالیومب – Persian" lang="fa" hreflang="fa" data-title="نیوالیومب" data-language-autonym="فارسی" data-language-local-name="Persian" class="interlanguage-link-target"><span>فارسی</span></a></li><li class="interlanguage-link interwiki-fr mw-list-item"><a href="https://fr.wikipedia.org/wiki/Nivolumab" title="Nivolumab – French" lang="fr" hreflang="fr" data-title="Nivolumab" data-language-autonym="Français" data-language-local-name="French" class="interlanguage-link-target"><span>Français</span></a></li><li class="interlanguage-link interwiki-ko mw-list-item"><a href="https://ko.wikipedia.org/wiki/%EC%98%B5%EB%94%94%EB%B3%B4" title="옵디보 – Korean" lang="ko" hreflang="ko" data-title="옵디보" data-language-autonym="한국어" data-language-local-name="Korean" class="interlanguage-link-target"><span>한국어</span></a></li><li class="interlanguage-link interwiki-it mw-list-item"><a href="https://it.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Italian" lang="it" hreflang="it" data-title="Nivolumab" data-language-autonym="Italiano" data-language-local-name="Italian" class="interlanguage-link-target"><span>Italiano</span></a></li><li class="interlanguage-link interwiki-ja mw-list-item"><a href="https://ja.wikipedia.org/wiki/%E3%83%8B%E3%83%9C%E3%83%AB%E3%83%9E%E3%83%96" title="ニボルマブ – Japanese" lang="ja" hreflang="ja" data-title="ニボルマブ" data-language-autonym="日本語" data-language-local-name="Japanese" class="interlanguage-link-target"><span>日本語</span></a></li><li class="interlanguage-link interwiki-no mw-list-item"><a href="https://no.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Norwegian Bokmål" lang="nb" hreflang="nb" data-title="Nivolumab" data-language-autonym="Norsk bokmål" data-language-local-name="Norwegian Bokmål" class="interlanguage-link-target"><span>Norsk bokmål</span></a></li><li class="interlanguage-link interwiki-or mw-list-item"><a href="https://or.wikipedia.org/wiki/%E0%AC%A8%E0%AC%BF%E0%AC%AD%E0%AD%8B%E0%AC%B2%E0%AD%81%E0%AC%AE%E0%AC%BE%E0%AC%AC" title="ନିଭୋଲୁମାବ – Odia" lang="or" hreflang="or" data-title="ନିଭୋଲୁମାବ" data-language-autonym="ଓଡ଼ିଆ" data-language-local-name="Odia" class="interlanguage-link-target"><span>ଓଡ଼ିଆ</span></a></li><li class="interlanguage-link interwiki-pl mw-list-item"><a href="https://pl.wikipedia.org/wiki/Niwolumab" title="Niwolumab – Polish" lang="pl" hreflang="pl" data-title="Niwolumab" data-language-autonym="Polski" data-language-local-name="Polish" class="interlanguage-link-target"><span>Polski</span></a></li><li class="interlanguage-link interwiki-ru mw-list-item"><a href="https://ru.wikipedia.org/wiki/%D0%9D%D0%B8%D0%B2%D0%BE%D0%BB%D1%83%D0%BC%D0%B0%D0%B1" title="Ниволумаб – Russian" lang="ru" hreflang="ru" data-title="Ниволумаб" data-language-autonym="Русский" data-language-local-name="Russian" class="interlanguage-link-target"><span>Русский</span></a></li><li class="interlanguage-link interwiki-sl mw-list-item"><a href="https://sl.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Slovenian" lang="sl" hreflang="sl" data-title="Nivolumab" data-language-autonym="Slovenščina" data-language-local-name="Slovenian" class="interlanguage-link-target"><span>Slovenščina</span></a></li><li class="interlanguage-link interwiki-tr mw-list-item"><a href="https://tr.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Turkish" lang="tr" hreflang="tr" data-title="Nivolumab" data-language-autonym="Türkçe" data-language-local-name="Turkish" class="interlanguage-link-target"><span>Türkçe</span></a></li><li class="interlanguage-link interwiki-vi mw-list-item"><a href="https://vi.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Vietnamese" lang="vi" hreflang="vi" data-title="Nivolumab" data-language-autonym="Tiếng Việt" data-language-local-name="Vietnamese" class="interlanguage-link-target"><span>Tiếng Việt</span></a></li><li class="interlanguage-link interwiki-zh mw-list-item"><a href="https://zh.wikipedia.org/wiki/%E7%BA%B3%E6%AD%A6%E5%88%A9%E5%B0%A4%E5%8D%95%E6%8A%97" title="纳武利尤单抗 – Chinese" lang="zh" hreflang="zh" data-title="纳武利尤单抗" data-language-autonym="中文" data-language-local-name="Chinese" class="interlanguage-link-target"><span>中文</span></a></li> </ul> <div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q7041828#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div> </div> </div> </div> </header> <div class="vector-page-toolbar"> <div class="vector-page-toolbar-container"> <div id="left-navigation"> <nav aria-label="Namespaces"> <div id="p-associated-pages" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-associated-pages" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-nstab-main" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Nivolumab" title="View the content page [c]" accesskey="c"><span>Article</span></a></li><li id="ca-talk" class="vector-tab-noicon mw-list-item"><a href="/wiki/Talk:Nivolumab" rel="discussion" title="Discuss improvements to the content page [t]" accesskey="t"><span>Talk</span></a></li> </ul> </div> </div> <div id="vector-variants-dropdown" class="vector-dropdown emptyPortlet" > <input type="checkbox" id="vector-variants-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-variants-dropdown" class="vector-dropdown-checkbox " aria-label="Change language variant" > <label id="vector-variants-dropdown-label" for="vector-variants-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" ><span class="vector-dropdown-label-text">English</span> </label> <div class="vector-dropdown-content"> <div id="p-variants" class="vector-menu mw-portlet mw-portlet-variants emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> </div> </div> </nav> </div> <div id="right-navigation" class="vector-collapsible"> <nav aria-label="Views"> <div id="p-views" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-views" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-view" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Nivolumab"><span>Read</span></a></li><li id="ca-edit" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Nivolumab&action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-history" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Nivolumab&action=history" title="Past revisions of this page [h]" accesskey="h"><span>View history</span></a></li> </ul> </div> </div> </nav> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-dropdown" class="vector-dropdown vector-page-tools-dropdown" > <input type="checkbox" id="vector-page-tools-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-tools-dropdown" class="vector-dropdown-checkbox " aria-label="Tools" > <label id="vector-page-tools-dropdown-label" for="vector-page-tools-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" ><span class="vector-dropdown-label-text">Tools</span> </label> <div class="vector-dropdown-content"> <div id="vector-page-tools-unpinned-container" class="vector-unpinned-container"> <div id="vector-page-tools" class="vector-page-tools vector-pinnable-element"> <div class="vector-pinnable-header vector-page-tools-pinnable-header vector-pinnable-header-unpinned" data-feature-name="page-tools-pinned" data-pinnable-element-id="vector-page-tools" data-pinned-container-id="vector-page-tools-pinned-container" data-unpinned-container-id="vector-page-tools-unpinned-container" > <div class="vector-pinnable-header-label">Tools</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-page-tools.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-page-tools.unpin">hide</button> </div> <div id="p-cactions" class="vector-menu mw-portlet mw-portlet-cactions emptyPortlet vector-has-collapsible-items" title="More options" > <div class="vector-menu-heading"> Actions </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-more-view" class="selected vector-more-collapsible-item mw-list-item"><a href="/wiki/Nivolumab"><span>Read</span></a></li><li id="ca-more-edit" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Nivolumab&action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-more-history" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Nivolumab&action=history"><span>View history</span></a></li> </ul> </div> </div> <div id="p-tb" class="vector-menu mw-portlet mw-portlet-tb" > <div class="vector-menu-heading"> General </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="t-whatlinkshere" class="mw-list-item"><a href="/wiki/Special:WhatLinksHere/Nivolumab" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j"><span>What links here</span></a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="/wiki/Special:RecentChangesLinked/Nivolumab" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k"><span>Related changes</span></a></li><li id="t-upload" class="mw-list-item"><a href="//en.wikipedia.org/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u"><span>Upload file</span></a></li><li id="t-permalink" class="mw-list-item"><a href="/w/index.php?title=Nivolumab&oldid=1269019282" title="Permanent link to this revision of this page"><span>Permanent link</span></a></li><li id="t-info" class="mw-list-item"><a href="/w/index.php?title=Nivolumab&action=info" title="More information about this page"><span>Page information</span></a></li><li id="t-cite" class="mw-list-item"><a href="/w/index.php?title=Special:CiteThisPage&page=Nivolumab&id=1269019282&wpFormIdentifier=titleform" title="Information on how to cite this page"><span>Cite this page</span></a></li><li id="t-urlshortener" class="mw-list-item"><a href="/w/index.php?title=Special:UrlShortener&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FNivolumab"><span>Get shortened URL</span></a></li><li id="t-urlshortener-qrcode" class="mw-list-item"><a href="/w/index.php?title=Special:QrCode&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FNivolumab"><span>Download QR code</span></a></li> </ul> </div> </div> <div id="p-coll-print_export" class="vector-menu mw-portlet mw-portlet-coll-print_export" > <div class="vector-menu-heading"> Print/export </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="coll-download-as-rl" class="mw-list-item"><a href="/w/index.php?title=Special:DownloadAsPdf&page=Nivolumab&action=show-download-screen" title="Download this page as a PDF file"><span>Download as PDF</span></a></li><li id="t-print" class="mw-list-item"><a href="/w/index.php?title=Nivolumab&printable=yes" title="Printable version of this page [p]" accesskey="p"><span>Printable version</span></a></li> </ul> </div> </div> <div id="p-wikibase-otherprojects" class="vector-menu mw-portlet mw-portlet-wikibase-otherprojects" > <div class="vector-menu-heading"> In other projects </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="t-wikibase" class="wb-otherproject-link wb-otherproject-wikibase-dataitem mw-list-item"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q7041828" title="Structured data on this page hosted by Wikidata [g]" accesskey="g"><span>Wikidata item</span></a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> </div> </div> </div> <div class="vector-column-end"> <div class="vector-sticky-pinned-container"> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-pinned-container" class="vector-pinned-container"> </div> </nav> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-pinned-container" class="vector-pinned-container"> <div id="vector-appearance" class="vector-appearance vector-pinnable-element"> <div class="vector-pinnable-header vector-appearance-pinnable-header vector-pinnable-header-pinned" data-feature-name="appearance-pinned" data-pinnable-element-id="vector-appearance" data-pinned-container-id="vector-appearance-pinned-container" data-unpinned-container-id="vector-appearance-unpinned-container" > <div class="vector-pinnable-header-label">Appearance</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-appearance.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-appearance.unpin">hide</button> </div> </div> </div> </nav> </div> </div> <div id="bodyContent" class="vector-body" aria-labelledby="firstHeading" data-mw-ve-target-container> <div class="vector-body-before-content"> <div class="mw-indicators"> </div> <div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div> </div> <div id="contentSub"><div id="mw-content-subtitle"></div></div> <div id="mw-content-text" class="mw-body-content"><div class="mw-content-ltr mw-parser-output" lang="en" dir="ltr"><div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Anticancer medication</div> <p class="mw-empty-elt"> </p> <div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Pharmaceutical compound</div> <style data-mw-deduplicate="TemplateStyles:r1269284339">@media screen{html.skin-theme-clientpref-night .mw-parser-output .dark_mode_safe img{background-color:var(--background-color-inverted,#f8f9fa)}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .dark_mode_safe img{background-color:var(--background-color-inverted,#f8f9fa)}}</style> <style data-mw-deduplicate="TemplateStyles:r1257001546">.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}@media screen{html.skin-theme-clientpref-night .mw-parser-output .infobox-full-data:not(.notheme)>div:not(.notheme)[style]{background:#1f1f23!important;color:#f8f9fa}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .infobox-full-data:not(.notheme) div:not(.notheme){background:#1f1f23!important;color:#f8f9fa}}@media(min-width:640px){body.skin--responsive .mw-parser-output .infobox-table{display:table!important}body.skin--responsive .mw-parser-output .infobox-table>caption{display:table-caption!important}body.skin--responsive .mw-parser-output .infobox-table>tbody{display:table-row-group}body.skin--responsive .mw-parser-output .infobox-table tr{display:table-row!important}body.skin--responsive .mw-parser-output .infobox-table th,body.skin--responsive .mw-parser-output .infobox-table td{padding-left:inherit;padding-right:inherit}}</style><table class="infobox" style="border-spacing:2px;"><caption class="infobox-title"><span title="International nonproprietary name (INN): Nivolumab">Nivolumab</span></caption><tbody><tr><td colspan="2" class="infobox-image"><span class="mw-default-size bg-transparent" typeof="mw:File/Frameless"><a href="/wiki/File:Nivolumab_5GGR.png" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/220px-Nivolumab_5GGR.png" decoding="async" width="220" height="253" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/330px-Nivolumab_5GGR.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/440px-Nivolumab_5GGR.png 2x" data-file-width="3564" data-file-height="4096" /></a></span><div class="infobox-caption"><a href="/wiki/Fragment_antigen-binding" class="mw-redirect" title="Fragment antigen-binding">Fab fragment</a> of nivolumab (blue) binding the <a href="/wiki/Extracellular_domain" class="mw-redirect" title="Extracellular domain">extracellular domain</a> of PD-1 (purple). From <a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB</a> entry <span class="plainlinks"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/pdbe/entry/pdb/5ggr">5ggr</a></span>.</div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd;color:inherit;"><a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">Monoclonal antibody</a></th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/File:Engineered_monoclonal_antibodies.svg" title="File:Engineered monoclonal antibodies.svg">Type</a></th><td class="infobox-data">Whole antibody</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Monoclonal_antibody#Production" title="Monoclonal antibody">Source</a></th><td class="infobox-data"><a href="/wiki/Human" title="Human">Human</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Antigen" title="Antigen">Target</a></th><td class="infobox-data"><a href="/wiki/Programmed_cell_death_1" class="mw-redirect" title="Programmed cell death 1">PD-1</a></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd;color:inherit;">Clinical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_nomenclature#Trade_names" title="Drug nomenclature">Trade names</a></th><td class="infobox-data">Opdivo</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">Other names</th><td class="infobox-data">ONO-4538, BMS-936558, MDX1106</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th><td class="infobox-data"><span title="www.drugs.com"><a rel="nofollow" class="external text" href="https://www.drugs.com/monograph/nivolumab.html">Monograph</a></span></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th><td class="infobox-data"><span title="medlineplus.gov"><a rel="nofollow" class="external text" href="https://medlineplus.gov/druginfo/meds/a614056.html">a614056</a></span></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">License data</a></th><td class="infobox-data"><style data-mw-deduplicate="TemplateStyles:r1126788409">.mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}</style><div class="plainlist"> <ul><li><small><abbr class="country-name" title="United States">US</abbr></small> <a href="/wiki/DailyMed" title="DailyMed">DailyMed</a>: <span title="dailymed.nlm.nih.gov"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nivolumab">Nivolumab</a></span></li></ul></div> </td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy<br />category</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"> <ul><li><small><abbr class="country-name" title="Australia">AU</abbr>:</small> D<sup id="cite_ref-Drugs.com_pregnancy_1-0" class="reference"><a href="#cite_note-Drugs.com_pregnancy-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup></li> <li>Use is not recommended<sup id="cite_ref-Drugs.com_pregnancy_1-1" class="reference"><a href="#cite_note-Drugs.com_pregnancy-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-AHFS2019_2-0" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup></li></ul> </div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes of<br />administration</a></th><td class="infobox-data"><a href="/wiki/Intravenous" class="mw-redirect" title="Intravenous">Intravenous</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_class" title="Drug class">Drug class</a></th><td class="infobox-data"><a href="/wiki/Immunotherapy" title="Immunotherapy">Immunotherapy</a><sup id="cite_ref-UK2019_3-0" class="reference"><a href="#cite_note-UK2019-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li><a href="/wiki/ATC_code_L01" title="ATC code L01">L01FF01</a> (<span title="www.whocc.no"><a rel="nofollow" class="external text" href="https://www.whocc.no/atc_ddd_index/?code=L01FF01">WHO</a></span>) </li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd;color:inherit;">Legal status</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"> <ul><li><small><abbr class="country-name" title="Australia">AU</abbr>:</small> <a href="/wiki/Standard_for_the_Uniform_Scheduling_of_Medicines_and_Poisons#Schedule_4" title="Standard for the Uniform Scheduling of Medicines and Poisons">S4</a> (Prescription only)<sup id="cite_ref-4" class="reference"><a href="#cite_note-4"><span class="cite-bracket">[</span>4<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span class="cite-bracket">[</span>5<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="Canada">CA</abbr></small>: <a href="/wiki/Prescription_drug" title="Prescription drug"> ℞-only</a> /<span class="nowrap"> </span>Schedule D<sup id="cite_ref-6" class="reference"><a href="#cite_note-6"><span class="cite-bracket">[</span>6<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span class="cite-bracket">[</span>7<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="United Kingdom">UK</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug">POM</a> (Prescription only)<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span class="cite-bracket">[</span>8<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="United States">US</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug">℞-only</a><sup id="cite_ref-Opdivo_FDA_label_9-0" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="European Union">EU</abbr>:</small> Rx-only<sup id="cite_ref-Opdivo_EPAR_10-0" class="reference"><a href="#cite_note-Opdivo_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup></li> <li>In general: ℞ (Prescription only)</li></ul></div> </td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd;color:inherit;"><a href="/wiki/Pharmacokinetics" title="Pharmacokinetics">Pharmacokinetic</a> data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Biological_half-life" title="Biological half-life">Elimination <span class="nowrap">half-life</span></a></th><td class="infobox-data">27 days<sup id="cite_ref-Opdivo_FDA_label_9-1" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd;color:inherit;">Identifiers</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Number</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li><span title="commonchemistry.cas.org"><a rel="nofollow" class="external text" href="https://commonchemistry.cas.org/detail?cas_rn=946414-94-4">946414-94-4</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li><span title="www.drugbank.ca"><a rel="nofollow" class="external text" href="https://www.drugbank.ca/drugs/DB09035">DB09035</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Unique_Ingredient_Identifier" title="Unique Ingredient Identifier">UNII</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li><span title="precision.fda.gov"><a rel="nofollow" class="external text" href="https://precision.fda.gov/uniisearch/srs/unii/31YO63LBSN">31YO63LBSN</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li><span title="www.kegg.jp"><a rel="nofollow" class="external text" href="https://www.kegg.jp/entry/D10316">D10316</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChEMBL" title="ChEMBL">ChEMBL</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409" /><div class="plainlist"><ul><li><span title="www.ebi.ac.uk"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chembl/explore/compound/ChEMBL2108738">ChEMBL2108738</a></span></li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd;color:inherit;">Chemical and physical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th><td class="infobox-data"><span title="Carbon">C</span><sub>6362</sub><span title="Hydrogen">H</span><sub>9862</sub><span title="Nitrogen">N</span><sub>1712</sub><span title="Oxygen">O</span><sub>1995</sub><span title="Sulfur">S</span><sub>42</sub></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Molar_mass" title="Molar mass">Molar mass</a></th><td class="infobox-data"><span class="nowrap"><span data-sort-value="7005143599390000000♠"></span>143<span style="margin-left:.25em;">599</span>.39</span> g·mol<sup>−1</sup></td></tr></tbody></table> <p><b>Nivolumab</b>, sold under the <a href="/wiki/Brand_name" class="mw-redirect" title="Brand name">brand name</a> <b>Opdivo</b>, is an <a href="/wiki/Anti-cancer_medication" class="mw-redirect" title="Anti-cancer medication">anti-cancer medication</a> used to treat a number of types of <a href="/wiki/Cancer" title="Cancer">cancer</a>.<sup id="cite_ref-AHFS2019_2-1" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> This includes <a href="/wiki/Melanoma" title="Melanoma">melanoma</a>, <a href="/wiki/Lung_cancer" title="Lung cancer">lung cancer</a>, <a href="/wiki/Malignant_pleural_mesothelioma" class="mw-redirect" title="Malignant pleural mesothelioma">malignant pleural mesothelioma</a>, <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a>, <a href="/wiki/Hodgkin_lymphoma" title="Hodgkin lymphoma">Hodgkin lymphoma</a>, <a href="/wiki/Head_and_neck_cancer" title="Head and neck cancer">head and neck cancer</a>, <a href="/wiki/Urothelial_carcinoma" class="mw-redirect" title="Urothelial carcinoma">urothelial carcinoma</a>, <a href="/wiki/Colon_cancer" class="mw-redirect" title="Colon cancer">colon cancer</a>, <a href="/wiki/Esophageal_squamous_cell_carcinoma" class="mw-redirect" title="Esophageal squamous cell carcinoma">esophageal squamous cell carcinoma</a>, <a href="/wiki/Liver_cancer" title="Liver cancer">liver cancer</a>, <a href="/wiki/Gastric_cancer" class="mw-redirect" title="Gastric cancer">gastric cancer</a>, and esophageal or gastroesophageal junction cancer.<sup id="cite_ref-Opdivo_FDA_label_9-2" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Opdivo_EPAR_10-1" class="reference"><a href="#cite_note-Opdivo_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-AHFS2019_2-2" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA_PR_20210416_11-0" class="reference"><a href="#cite_note-FDA_PR_20210416-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA_nivolumab_20210520_12-0" class="reference"><a href="#cite_note-FDA_nivolumab_20210520-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup> It is administered <a href="/wiki/Intravenous" class="mw-redirect" title="Intravenous">intravenously</a>.<sup id="cite_ref-Opdivo_FDA_label_9-3" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Opdivo_EPAR_10-2" class="reference"><a href="#cite_note-Opdivo_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-AHFS2019_2-3" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p><p>The most common side effects include fatigue, rash, musculoskeletal pain, <a href="/wiki/Pruritus" class="mw-redirect" title="Pruritus">pruritus</a> (itching), diarrhea, nausea, <a href="/wiki/Asthenia" class="mw-redirect" title="Asthenia">asthenia</a> (weakness), cough, <a href="/wiki/Dyspnea" class="mw-redirect" title="Dyspnea">dyspnea</a> (shortness of breath), constipation, decreased appetite, back pain, <a href="/wiki/Arthralgia" title="Arthralgia">arthralgia</a> (joint pain), upper respiratory tract infection, <a href="/wiki/Pyrexia" class="mw-redirect" title="Pyrexia">pyrexia</a> (fever), headache, abdominal pain, and vomiting.<sup id="cite_ref-FDA_nivolumab_20210520_12-1" class="reference"><a href="#cite_note-FDA_nivolumab_20210520-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup> Use during pregnancy may harm the baby.<sup id="cite_ref-Drugs.com_pregnancy_1-2" class="reference"><a href="#cite_note-Drugs.com_pregnancy-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-AHFS2019_2-4" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> Nivolumab is a human <a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">IgG4</a> <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> that <a href="/wiki/PD-1_and_PD-L1_inhibitors" title="PD-1 and PD-L1 inhibitors">blocks PD-1</a>.<sup id="cite_ref-AHFS2019_2-5" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> It is a type of <a href="/wiki/Immunotherapy" title="Immunotherapy">immunotherapy</a> and works as a <a href="/wiki/Checkpoint_inhibitor" title="Checkpoint inhibitor">checkpoint inhibitor</a>, blocking a signal that prevents activation of <a href="/wiki/T_cells" class="mw-redirect" title="T cells">T cells</a> from attacking the cancer.<sup id="cite_ref-AHFS2019_2-6" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-UK2019_3-1" class="reference"><a href="#cite_note-UK2019-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup> The most common side effects when used in combination with chemotherapy include peripheral neuropathy (damage to the nerves outside of the brain and spinal cord), nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation and musculoskeletal pain.<sup id="cite_ref-FDA_PR_20210416_11-1" class="reference"><a href="#cite_note-FDA_PR_20210416-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup> </p><p>Nivolumab was approved for medical use in the United States in 2014.<sup id="cite_ref-AHFS2019_2-7" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Opdivo_FDA_label_9-4" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> It is on the <a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">World Health Organization's List of Essential Medicines</a>.<sup id="cite_ref-WHO23rd_13-0" class="reference"><a href="#cite_note-WHO23rd-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup> It is made using <a href="/wiki/Chinese_hamster_ovary_cell" title="Chinese hamster ovary cell">Chinese hamster ovary cells</a>.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup> Nivolumab is the second FDA-approved systemic therapy for mesothelioma<sup id="cite_ref-FDA_PR_20201002_15-0" class="reference"><a href="#cite_note-FDA_PR_20201002-15"><span class="cite-bracket">[</span>15<span class="cite-bracket">]</span></a></sup> and is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.<sup id="cite_ref-FDA_PR_20210416_11-2" class="reference"><a href="#cite_note-FDA_PR_20210416-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup> </p> <meta property="mw:PageProp/toc" /> <div class="mw-heading mw-heading2"><h2 id="Medical_uses">Medical uses</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=1" title="Edit section: Medical uses"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In the US, nivolumab is <a href="/wiki/Indication_(medicine)" title="Indication (medicine)">indicated</a> to treat: </p> <div><ul><li>Unresectable or metastatic melanoma<sup id="cite_ref-Opdivo_FDA_label_9-5" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Adjuvant treatment of melanoma<sup id="cite_ref-Opdivo_FDA_label_9-6" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Metastatic non-small cell lung cancer<sup id="cite_ref-Opdivo_FDA_label_9-7" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Malignant pleural mesothelioma<sup id="cite_ref-Opdivo_FDA_label_9-8" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Advanced renal cell carcinoma<sup id="cite_ref-Opdivo_FDA_label_9-9" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Classical Hodgkin's lymphoma<sup id="cite_ref-Opdivo_FDA_label_9-10" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Squamous-cell carcinoma of the head and neck<sup id="cite_ref-Opdivo_FDA_label_9-11" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Urothelial carcinoma<sup id="cite_ref-Opdivo_FDA_label_9-12" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer<sup id="cite_ref-Opdivo_FDA_label_9-13" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Hepatocellular carcinoma<sup id="cite_ref-Opdivo_FDA_label_9-14" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Esophageal cancer<sup id="cite_ref-Opdivo_FDA_label_9-15" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li><li>Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma<sup id="cite_ref-Opdivo_FDA_label_9-16" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li></ul></div> <p>Nivolumab is used as a first-line treatment for inoperable or <a href="/wiki/Metastatic_melanoma" class="mw-redirect" title="Metastatic melanoma">metastatic melanoma</a> in combination with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a> if the cancer does not have a mutation in <a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a>,<sup id="cite_ref-Opdivo_FDA_label_9-17" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> and as a second-line treatment for inoperable or metastatic melanoma following treatment with ipilimumab and, if the cancer has a BRAF mutation, a <a href="/wiki/BRAF_inhibitor" class="mw-redirect" title="BRAF inhibitor">BRAF inhibitor</a>.<sup id="cite_ref-Opdivo_FDA_label_9-18" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-2015revMel_16-0" class="reference"><a href="#cite_note-2015revMel-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> It is also used to treat metastatic squamous <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">non-small cell lung cancer</a> with progression with or after <a href="/wiki/Platinum-based_antineoplastic" title="Platinum-based antineoplastic">platinum-based drugs</a>, and for treatment of <a href="/wiki/Small_cell_lung_cancer" class="mw-redirect" title="Small cell lung cancer">small cell lung cancer</a>.<sup id="cite_ref-Opdivo_FDA_label_9-19" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-2015revNSCLC_17-0" class="reference"><a href="#cite_note-2015revNSCLC-17"><span class="cite-bracket">[</span>17<span class="cite-bracket">]</span></a></sup> It also used as a second-line treatment for <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a> after <a href="/wiki/Anti-angiogenic" class="mw-redirect" title="Anti-angiogenic">anti-angiogenic</a> treatment has failed.<sup id="cite_ref-Opdivo_FDA_label_9-20" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> </p><p>Nivolumab is used for primary or metastatic <a href="/wiki/Urothelial_carcinoma" class="mw-redirect" title="Urothelial carcinoma">urothelial carcinoma</a>, the most common form of <a href="/wiki/Bladder_cancer" title="Bladder cancer">bladder cancer</a>. It can be used for locally advanced or metastatic disease that progresses during or following <a href="/wiki/Platinum-based_antineoplastic" title="Platinum-based antineoplastic">platinum-based chemotherapy</a> or progresses within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18"><span class="cite-bracket">[</span>18<span class="cite-bracket">]</span></a></sup> </p><p>Nivolumab is indicated for the adjuvant treatment of melanoma with lymph node involvement as well as in metastatic disease with previous complete resection.<sup id="cite_ref-Opdivo_FDA_label_9-21" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-19" class="reference"><a href="#cite_note-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> </p><p>The combination of nivolumab with ipilimumab is used for the first-line treatment of adults with inoperable <a href="/wiki/Malignant_pleural_mesothelioma" class="mw-redirect" title="Malignant pleural mesothelioma">malignant pleural mesothelioma</a>.<sup id="cite_ref-Opdivo_FDA_label_9-22" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA_PR_20201002_15-1" class="reference"><a href="#cite_note-FDA_PR_20201002-15"><span class="cite-bracket">[</span>15<span class="cite-bracket">]</span></a></sup> </p><p>In April 2021, the US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.<sup id="cite_ref-FDA_PR_20210416_11-3" class="reference"><a href="#cite_note-FDA_PR_20210416-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup> In May 2021, the FDA approved nivolumab for the treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant <a href="/wiki/Chemoradiotherapy" title="Chemoradiotherapy">chemoradiotherapy</a>.<sup id="cite_ref-FDA_nivolumab_20210520_12-2" class="reference"><a href="#cite_note-FDA_nivolumab_20210520-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup> </p><p>In August 2021, the FDA approved nivolumab for the adjuvant treatment of urothelial carcinoma who are at high risk of recurrence after undergoing <a href="/wiki/Radical_surgery" title="Radical surgery">radical resection</a>.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20"><span class="cite-bracket">[</span>20<span class="cite-bracket">]</span></a></sup> </p><p>In May 2022, the FDA expanded the indication to include the first-line treatment of people with advanced or metastatic esophageal squamous cell carcinoma.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span class="cite-bracket">[</span>21<span class="cite-bracket">]</span></a></sup> In the same year, the FDA approved a combination therapy consisting of <a href="/wiki/Relatlimab" title="Relatlimab">relatlimab</a> and nivolumab for the treatment of some cases of advanced melanoma.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span class="cite-bracket">[</span>22<span class="cite-bracket">]</span></a></sup> </p><p>In March 2024, the FDA approved nivolumab, in combination with <a href="/wiki/Cisplatin" title="Cisplatin">cisplatin</a> and <a href="/wiki/Gemcitabine" title="Gemcitabine">gemcitabine</a>, as a first-line treatment for adults with unresectable or metastatic <a href="/wiki/Transitional_cell_carcinoma" title="Transitional cell carcinoma">urothelial carcinoma</a>.<sup id="cite_ref-FDA_20240306_23-0" class="reference"><a href="#cite_note-FDA_20240306-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span class="cite-bracket">[</span>24<span class="cite-bracket">]</span></a></sup> </p><p>In October 2024, the FDA approved nivolumab with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.<sup id="cite_ref-FDA_PR_20241004_25-0" class="reference"><a href="#cite_note-FDA_PR_20241004-25"><span class="cite-bracket">[</span>25<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-26" class="reference"><a href="#cite_note-26"><span class="cite-bracket">[</span>26<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Side_effects">Side effects</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=2" title="Edit section: Side effects"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>The US FDA prescription label contains warnings regarding increased risk for severe immune-mediated inflammation of <a href="/wiki/Pneumonitis" title="Pneumonitis">the lungs</a>, <a href="/wiki/Colitis" title="Colitis">colon</a>, <a href="/wiki/Hepatitis" title="Hepatitis">liver</a>, and <a href="/wiki/Nephritis" title="Nephritis">kidneys</a> (with accompanying kidney dysfunction), as well as immune-mediated <a href="/wiki/Hypothyroidism" title="Hypothyroidism">hypothyroidism</a> and <a href="/wiki/Hyperthyroidism" title="Hyperthyroidism">hyperthyroidism</a>.<sup id="cite_ref-Opdivo_FDA_label_9-23" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> Hypothyroidism and hyperthyroidism may affect 8.5% and 3.7% of patients, respectively.<sup id="cite_ref-DeFilette2019_27-0" class="reference"><a href="#cite_note-DeFilette2019-27"><span class="cite-bracket">[</span>27<span class="cite-bracket">]</span></a></sup> Autoimmune diabetes similar to <a href="/wiki/Diabetes_mellitus_type_1" class="mw-redirect" title="Diabetes mellitus type 1">diabetes mellitus type 1</a> may occur in approximately 2% of people treated with nivolumab.<sup id="cite_ref-DeFilette2019_27-1" class="reference"><a href="#cite_note-DeFilette2019-27"><span class="cite-bracket">[</span>27<span class="cite-bracket">]</span></a></sup> </p><p>In trials for melanoma, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: rash and itchy skin, cough, upper respiratory tract infections, and peripheral edema. Other clinically important side effects with less than 10% frequency were ventricular arrhythmia, inflammation of parts of the eye (<a href="/wiki/Iridocyclitis" class="mw-redirect" title="Iridocyclitis">iridocyclitis</a>), infusion-related reactions,<sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Vagueness" title="Wikipedia:Vagueness"><span title="This information is too vague. (March 2025)">vague</span></a></i>]</sup> dizziness, peripheral and sensory <a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">neuropathy</a>, peeling skin, <a href="/wiki/Erythema_multiforme" title="Erythema multiforme">erythema multiforme</a>, <a href="/wiki/Vitiligo" title="Vitiligo">vitiligo</a>, and <a href="/wiki/Psoriasis" title="Psoriasis">psoriasis</a>.<sup id="cite_ref-Opdivo_FDA_label_9-24" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> </p><p>In trials for lung cancer, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: fatigue, weakness, edema, fever, chest pain, generalized pain, shortness of breath, cough, muscle and joint pain, decreased appetite, abdominal pain, nausea and vomiting, constipation, weight loss, rash, and itchy skin.<sup id="cite_ref-Opdivo_FDA_label_9-25" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> Levels of electrolytes and blood cells counts were also disrupted.<sup id="cite_ref-Opdivo_FDA_label_9-26" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Pregnancy_and_breastfeeding">Pregnancy and breastfeeding</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=3" title="Edit section: Pregnancy and breastfeeding"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Use during pregnancy may harm the baby.<sup id="cite_ref-Drugs.com_pregnancy_1-3" class="reference"><a href="#cite_note-Drugs.com_pregnancy-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Opdivo_FDA_label_9-27" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-AHFS2019_2-8" class="reference"><a href="#cite_note-AHFS2019-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Pharmacokinetics">Pharmacokinetics</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=4" title="Edit section: Pharmacokinetics"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Based on data from 909 patients, the <a href="/wiki/Terminal_half-life" class="mw-redirect" title="Terminal half-life">terminal half-life</a> of nivolumab is 26.7 days and steady-state concentrations were reached by 12 weeks when administered at 3 mg/kg every two weeks.<sup id="cite_ref-Opdivo_FDA_label_9-28" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup class="reference nowrap"><span title="Page / location: 29">: 29 </span></sup> Age, gender, race, baseline <a href="/wiki/Lactate_dehydrogenase" title="Lactate dehydrogenase">LDH</a>, <a href="/wiki/PD-L1" title="PD-L1">PD-L1</a> expression, tumor type, tumor size, renal impairment, and mild hepatic impairment do not affect clearance of the drug.<sup id="cite_ref-Opdivo_FDA_label_9-29" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup class="reference nowrap"><span title="Page / location: 30">: 30 </span></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Mechanism_of_action">Mechanism of action</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=5" title="Edit section: Mechanism of action"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Nivolumab's mechanism of action is based on its role as a monoclonal antibody that selectively binds to the <a href="/wiki/Programmed_cell_death_protein_1" title="Programmed cell death protein 1">programmed death-1</a> (PD-1) receptor on the surface of <a href="/wiki/T_cell" title="T cell">T cells</a>, a type of <a href="/wiki/White_blood_cell" title="White blood cell">white blood cell</a> that plays a crucial role in the immune system’s ability to <a href="/wiki/Immune_system#Tumor_immunology" title="Immune system">combat malignancies</a>.<sup id="cite_ref-Pardoll2012_28-0" class="reference"><a href="#cite_note-Pardoll2012-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:0_29-0" class="reference"><a href="#cite_note-:0-29"><span class="cite-bracket">[</span>29<span class="cite-bracket">]</span></a></sup> Normally, certain cancer cells exploit the PD-1 pathway to shield themselves from the immune response by expressing <a href="/wiki/PD-L1" title="PD-L1">programmed death-ligand 1</a> (PD-L1), which interacts with the PD-1 receptor and inhibits T-cell activation and proliferation. Nivolumab interrupts this interaction by binding to the PD-1 receptor, thereby <a href="/wiki/Immune_checkpoint_blockade" class="mw-redirect" title="Immune checkpoint blockade">blocking</a> tumor cells from evading immune detection. This blockade enhances T-cell response, boosts the immune system's anti-tumor activity, and ultimately contributes to the destruction of cancer cells.<sup id="cite_ref-Pardoll2012_28-1" class="reference"><a href="#cite_note-Pardoll2012-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:0_29-1" class="reference"><a href="#cite_note-:0-29"><span class="cite-bracket">[</span>29<span class="cite-bracket">]</span></a></sup> </p><p>PD-1 is a protein located on the surface of T cells that have been activated in the body's immune response. Normally, the immune system is controlled in part by certain molecules, such as PD-L1 or <a href="/wiki/PD-L2" class="mw-redirect" title="PD-L2">PD-L2</a>, which can bind to PD-1. When they do, they prevent the T cell from taking action, which helps to ensure the body does not have an excessive immune reaction.<sup id="cite_ref-:0_29-2" class="reference"><a href="#cite_note-:0-29"><span class="cite-bracket">[</span>29<span class="cite-bracket">]</span></a></sup> However, many cancer cells take advantage of this system by producing PD-L1 themselves, effectively shutting down T cells and protecting the tumor from an immune attack. Nivolumab interferes with this process—it attaches to PD-1 and prevents PD-L1 from binding to it, which frees the T cells to target and destroy the tumor.<sup id="cite_ref-Pardoll2012_28-2" class="reference"><a href="#cite_note-Pardoll2012-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:0_29-3" class="reference"><a href="#cite_note-:0-29"><span class="cite-bracket">[</span>29<span class="cite-bracket">]</span></a></sup> Approximately 40–50% of melanoma cells express PD-L1. Aside from this, PD-L1 is not commonly found in the body, though it is present in certain areas such as the lining of the respiratory tract and in placental tissue.<sup id="cite_ref-2015revMel_16-1" class="reference"><a href="#cite_note-2015revMel-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Physical_properties">Physical properties</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=6" title="Edit section: Physical properties"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Nivolumab is a fully human monoclonal <a href="/wiki/Immunoglobulin_G4" class="mw-redirect" title="Immunoglobulin G4">immunoglobulin G4</a> antibody to <a href="/wiki/PD-1" class="mw-redirect" title="PD-1">PD-1</a>.<sup id="cite_ref-2015revMel_16-2" class="reference"><a href="#cite_note-2015revMel-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> The gamma 1 heavy chain is 91.8% unmodified human design while the kappa light chain is 98.9%.<sup id="cite_ref-INN_30-0" class="reference"><a href="#cite_note-INN-30"><span class="cite-bracket">[</span>30<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="History">History</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=7" title="Edit section: History"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>It was invented at <a href="/wiki/Medarex" title="Medarex">Medarex</a> through a research collaboration with Ono.<sup id="cite_ref-auto_31-0" class="reference"><a href="#cite_note-auto-31"><span class="cite-bracket">[</span>31<span class="cite-bracket">]</span></a></sup> Under the agreement between the companies in 2005, Medarex held an exclusive right of nivolumab in North America, and Ono retained the right in all other countries except North America. <a href="/wiki/Bristol-Myers_Squibb" class="mw-redirect" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a> acquired Medarex in 2009, for $2.4B.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span class="cite-bracket">[</span>32<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span class="cite-bracket">[</span>33<span class="cite-bracket">]</span></a></sup> Ono received approval from Japanese regulatory authorities to use nivolumab to treat unresectable melanoma in July 2014, which was the first regulatory approval of a PD-1 inhibitor.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span class="cite-bracket">[</span>34<span class="cite-bracket">]</span></a></sup> </p><p>Nivolumab received US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) approval for the treatment of melanoma in December 2014.<sup id="cite_ref-2015revMel_16-3" class="reference"><a href="#cite_note-2015revMel-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-35" class="reference"><a href="#cite_note-35"><span class="cite-bracket">[</span>35<span class="cite-bracket">]</span></a></sup> In April 2015, the <a href="/wiki/Committee_for_Medicinal_Products_for_Human_Use" title="Committee for Medicinal Products for Human Use">Committee for Medicinal Products for Human Use</a> of the <a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">European Medicines Agency</a> (EMA) recommended approval of nivolumab for metastatic melanoma as a <a href="/wiki/Monotherapy" class="mw-redirect" title="Monotherapy">monotherapy</a>.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36"><span class="cite-bracket">[</span>36<span class="cite-bracket">]</span></a></sup> </p><p>In March 2015, the FDA approved it for the treatment of <a href="/wiki/Squamous-cell_carcinoma_of_the_lung" title="Squamous-cell carcinoma of the lung">squamous cell lung cancer</a>.<sup id="cite_ref-FDA2015-Mar_37-0" class="reference"><a href="#cite_note-FDA2015-Mar-37"><span class="cite-bracket">[</span>37<span class="cite-bracket">]</span></a></sup> </p><p>In June 2015, the EMA granted a marketing authorization valid throughout the European Union.<sup id="cite_ref-Opdivo_EPAR_10-3" class="reference"><a href="#cite_note-Opdivo_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup> </p><p>In November 2015, the FDA approved nivolumab as a second-line treatment for <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a> after having granted the application <a href="/wiki/Breakthrough_therapy" title="Breakthrough therapy">breakthrough therapy</a> designation, <a href="/wiki/Fast_track_(FDA)" title="Fast track (FDA)">fast track</a> designation, and <a href="/wiki/Priority_review_(FDA)" class="mw-redirect" title="Priority review (FDA)">priority review</a> status.<sup id="cite_ref-FDApress2015renal_38-0" class="reference"><a href="#cite_note-FDApress2015renal-38"><span class="cite-bracket">[</span>38<span class="cite-bracket">]</span></a></sup> </p><p>In May 2016, the FDA approved nivolumab for the treatment of people with <a href="/wiki/Classical_Hodgkin_lymphoma" class="mw-redirect" title="Classical Hodgkin lymphoma">classical Hodgkin lymphoma</a> who have relapsed or progressed after <a href="/wiki/Autologous_hematopoietic_stem_cell_transplantation" class="mw-redirect" title="Autologous hematopoietic stem cell transplantation">autologous hematopoietic stem cell transplantation</a> and post-transplantation <a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">brentuximab vedotin</a>.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span class="cite-bracket">[</span>39<span class="cite-bracket">]</span></a></sup> </p><p>In December 2017, the FDA granted approval to nivolumab for adjuvant treatment of melanoma with involvement of lymph nodes or for metastatic disease with complete resection.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40"><span class="cite-bracket">[</span>40<span class="cite-bracket">]</span></a></sup> </p><p>In April 2018, the FDA granted approval to nivolumab in combination with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a> for the first-line treatment of people with intermediate and poor risk advanced <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a>.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41"><span class="cite-bracket">[</span>41<span class="cite-bracket">]</span></a></sup> </p><p>In June 2018, China's Drug Administration approved nivolumab, the country's first immuno-oncology and the first PD-1 therapy.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span class="cite-bracket">[</span>42<span class="cite-bracket">]</span></a></sup> </p><p>In October 2020, the US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) approved the combination of nivolumab with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery.<sup id="cite_ref-FDA_PR_20201002_15-2" class="reference"><a href="#cite_note-FDA_PR_20201002-15"><span class="cite-bracket">[</span>15<span class="cite-bracket">]</span></a></sup> </p><p>In April 2021, the FDA approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of people with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.<sup id="cite_ref-FDA_PR_20210416_11-4" class="reference"><a href="#cite_note-FDA_PR_20210416-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup> </p><p>In March 2024, the FDA approved nivolumab, in combination with cisplatin and gemcitabine, for first-line treatment of adults with unresectable or metastatic urothelial carcinoma.<sup id="cite_ref-FDA_20240306_23-1" class="reference"><a href="#cite_note-FDA_20240306-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup> Efficacy was evaluated in CHECKMATE-901 (NCT03036098), a randomized, open-label trial enrolling 608 participants with previously untreated unresectable or metastatic urothelial carcinoma.<sup id="cite_ref-FDA_20240306_23-2" class="reference"><a href="#cite_note-FDA_20240306-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup> Participants were randomized (1:1) to receive either nivolumab in combination with cisplatin and gemcitabine (up to six cycles) followed by nivolumab alone for up to two years or cisplatin and gemcitabine (up to six cycles).<sup id="cite_ref-FDA_20240306_23-3" class="reference"><a href="#cite_note-FDA_20240306-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup> On both arms, participants discontinuing cisplatin were permitted to receive carboplatin.<sup id="cite_ref-FDA_20240306_23-4" class="reference"><a href="#cite_note-FDA_20240306-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup> Randomization was stratified by tumor PD-L1 expression and presence of liver metastasis.<sup id="cite_ref-FDA_20240306_23-5" class="reference"><a href="#cite_note-FDA_20240306-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Research">Research</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=8" title="Edit section: Research"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Nivolumab, and other PD-1 inhibitors, appear to be effective in people with brain metastases<sup id="cite_ref-43" class="reference"><a href="#cite_note-43"><span class="cite-bracket">[</span>43<span class="cite-bracket">]</span></a></sup> and for cancer in people with autoimmune diseases.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44"><span class="cite-bracket">[</span>44<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Hodgkin's_lymphoma"><span id="Hodgkin.27s_lymphoma"></span>Hodgkin's lymphoma</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=9" title="Edit section: Hodgkin's lymphoma"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In <a href="/wiki/Hodgkin%27s_lymphoma" class="mw-redirect" title="Hodgkin's lymphoma">Hodgkin's lymphoma</a>, <a href="/wiki/Reed%E2%80%93Sternberg_cell" title="Reed–Sternberg cell">Reed–Sternberg cells</a> harbor amplification of <a href="/wiki/Chromosome_9" title="Chromosome 9">chromosome 9p</a>24.1, which encodes PD-L1 and PD-L2, and leads to their constitutive expression. In a small clinical study published in 2015, nivolumab elicited an objective response in 87% of a cohort of 20 patients.<sup id="cite_ref-Science2015rev_45-0" class="reference"><a href="#cite_note-Science2015rev-45"><span class="cite-bracket">[</span>45<span class="cite-bracket">]</span></a></sup> </p><p>The evidence for a favorable effect of nivolumab on overall survival, quality of life, progression-free survival, and complete response among individuals with Hodgkin's lymphoma is uncertain.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46"><span class="cite-bracket">[</span>46<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Biomarkers">Biomarkers</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=10" title="Edit section: Biomarkers"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Amplification of chromosome 9p24 may serve as a predictive biomarker in Hodgkin's lymphoma.<sup id="cite_ref-Science2015rev_45-1" class="reference"><a href="#cite_note-Science2015rev-45"><span class="cite-bracket">[</span>45<span class="cite-bracket">]</span></a></sup> </p><p>Every manufacturer pursuing drug development using monoclonal antibodies against PD-1 has developed assays to measure PD-L1 level as a potential biomarker using the antibody as the <a href="/wiki/Analyte-specific_reagent" title="Analyte-specific reagent">analyte-specific reagent</a>. Bristol Myers Squibb partnered with Dako on a nivolumab-based assay. However, as of 2015 the complexity of the immune response had hindered efforts to identify people who would be likely to respond well to PD-1 inhibitors.<sup id="cite_ref-Science2015rev_45-2" class="reference"><a href="#cite_note-Science2015rev-45"><span class="cite-bracket">[</span>45<span class="cite-bracket">]</span></a></sup> PD-L1 levels appeared to be dynamic and modulated by several factors, and efforts to correlate PD-L1 levels before or during treatment with treatment response or duration of response had failed to reveal any useful correlations as of 2015.<sup id="cite_ref-2015revMel_16-4" class="reference"><a href="#cite_note-2015revMel-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Lung_cancer">Lung cancer</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=11" title="Edit section: Lung cancer"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In 2016, Bristol Myers Squibb announced the results of a clinical trial in which nivolumab failed to achieve its endpoint and was no better than traditional chemotherapy at treating newly diagnosed lung cancer.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47"><span class="cite-bracket">[</span>47<span class="cite-bracket">]</span></a></sup> Bristol Myers Squibb went on to attempt to gain approval for a combination therapy for lung cancer that included nivolumab and the company's older drug ipilimumab. The application was withdrawn in early 2019 following disappointing results.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48"><span class="cite-bracket">[</span>48<span class="cite-bracket">]</span></a></sup> </p><p>Infusion durations of 60 minutes and 30 minutes appear to have similar pharmacokinetics (absorption, distribution, metabolism, and elimination).<sup id="cite_ref-Waterhouse_2018_49-0" class="reference"><a href="#cite_note-Waterhouse_2018-49"><span class="cite-bracket">[</span>49<span class="cite-bracket">]</span></a></sup> </p><p>Nivolumab is indicated for the treatment of people with metastatic squamous <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">non-small cell lung cancer</a> with progression on or after platinum-based chemotherapy.<sup id="cite_ref-Opdivo_FDA_label_9-30" class="reference"><a href="#cite_note-Opdivo_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> CHECKMATE-227<sup id="cite_ref-:1_50-0" class="reference"><a href="#cite_note-:1-50"><span class="cite-bracket">[</span>50<span class="cite-bracket">]</span></a></sup> tested the combination of nivolumab and ipilimumab in participants with stage IV or recurrent non-small cell lung cancer without previous treatment.<sup id="cite_ref-:2_51-0" class="reference"><a href="#cite_note-:2-51"><span class="cite-bracket">[</span>51<span class="cite-bracket">]</span></a></sup> Participants with a PD-L1 expression level of 1% or more were randomized in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or standard chemotherapy.<sup id="cite_ref-:2_51-1" class="reference"><a href="#cite_note-:2-51"><span class="cite-bracket">[</span>51<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:1_50-1" class="reference"><a href="#cite_note-:1-50"><span class="cite-bracket">[</span>50<span class="cite-bracket">]</span></a></sup> The chemotherapeutics used were <a href="/wiki/Cisplatin" title="Cisplatin">cisplatin</a> or <a href="/wiki/Carboplatin" title="Carboplatin">carboplatin</a> combined with <a href="/wiki/Gemcitabine" title="Gemcitabine">gemcitabine</a> for people with squamous-cell non-small cell lung cancer, or pemetrexed for those with nonsquamous disease.<sup id="cite_ref-:1_50-2" class="reference"><a href="#cite_note-:1-50"><span class="cite-bracket">[</span>50<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:2_51-2" class="reference"><a href="#cite_note-:2-51"><span class="cite-bracket">[</span>51<span class="cite-bracket">]</span></a></sup> The overall survival was 17.1, 15.7, and 14.9 months, respectively.<sup id="cite_ref-:2_51-3" class="reference"><a href="#cite_note-:2-51"><span class="cite-bracket">[</span>51<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:1_50-3" class="reference"><a href="#cite_note-:1-50"><span class="cite-bracket">[</span>50<span class="cite-bracket">]</span></a></sup> The participants who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy.<sup id="cite_ref-:2_51-4" class="reference"><a href="#cite_note-:2-51"><span class="cite-bracket">[</span>51<span class="cite-bracket">]</span></a></sup> The overall survival among that group was 17.2, 15.2 and 12.2 months, respectively.<sup id="cite_ref-:1_50-4" class="reference"><a href="#cite_note-:1-50"><span class="cite-bracket">[</span>50<span class="cite-bracket">]</span></a></sup> </p><p>In June 2023, Bristol Myers Squibb provided positive four-year follow-up results from a phase III study (CheckMate-9LA<sup id="cite_ref-auto1_52-0" class="reference"><a href="#cite_note-auto1-52"><span class="cite-bracket">[</span>52<span class="cite-bracket">]</span></a></sup>) of a combination of nivolumab and ipilimumab along with chemotherapy, compared to chemotherapy alone, as first-line treatment in people with metastatic non-small cell lung cancer. The trial found an overall survival of 21% at a median follow-up of 47.9 months among those treated with the dual immunotherapy-based combination compared to 16% of participants treated with chemotherapy alone.<sup id="cite_ref-auto1_52-1" class="reference"><a href="#cite_note-auto1-52"><span class="cite-bracket">[</span>52<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span class="cite-bracket">[</span>53<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Melanoma">Melanoma</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=12" title="Edit section: Melanoma"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>PD-L1 is expressed in 40-50% of melanomas.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54"><span class="cite-bracket">[</span>54<span class="cite-bracket">]</span></a></sup> Phase I and II clinical trials have shown nivolumab as a promising and durable treatment option in melanoma as a single agent and in combination with ipilimumab.<sup id="cite_ref-2015revMel_16-5" class="reference"><a href="#cite_note-2015revMel-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> Phase III trials are ongoing.<sup id="cite_ref-:3_55-0" class="reference"><a href="#cite_note-:3-55"><span class="cite-bracket">[</span>55<span class="cite-bracket">]</span></a></sup> </p><p>In October 2022, the results of a phase III trial, CheckMate -76K, showed that Opdivo reduced the risk of death by 58% as an adjuvant therapy in participants with completely resected stage two melanoma, the most serious type of skin cancer.<sup id="cite_ref-:3_55-1" class="reference"><a href="#cite_note-:3-55"><span class="cite-bracket">[</span>55<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-56" class="reference"><a href="#cite_note-56"><span class="cite-bracket">[</span>56<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Urothelial_carcinoma">Urothelial carcinoma</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=13" title="Edit section: Urothelial carcinoma"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In February 2023, Bristol Myers Squibb reported that the three-year follow-up results from its phase III (CheckMate-274) trial of nivolumab showed significant sustained clinical benefits with nivolumab for the adjuvant treatment of participants with muscle-invasive urothelial carcinoma at a high risk of recurrence after radical resection.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57"><span class="cite-bracket">[</span>57<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-58" class="reference"><a href="#cite_note-58"><span class="cite-bracket">[</span>58<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="See_also">See also</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=14" title="Edit section: See also"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <ul><li><a href="/wiki/Nivolumab/relatlimab" title="Nivolumab/relatlimab">Nivolumab/relatlimab</a></li></ul> <div class="mw-heading mw-heading2"><h2 id="References">References</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=15" title="Edit section: References"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <style data-mw-deduplicate="TemplateStyles:r1239543626">.mw-parser-output .reflist{margin-bottom:0.5em;list-style-type:decimal}@media screen{.mw-parser-output .reflist{font-size:90%}}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class="reflist"> <div class="mw-references-wrap mw-references-columns"><ol class="references"> <li id="cite_note-Drugs.com_pregnancy-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Drugs.com_pregnancy_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Drugs.com_pregnancy_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Drugs.com_pregnancy_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Drugs.com_pregnancy_1-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><style data-mw-deduplicate="TemplateStyles:r1238218222">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#d33)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#d33)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}}</style><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.drugs.com/pregnancy/nivolumab.html">"Nivolumab (Opdivo) Use During Pregnancy"</a>. <i>Drugs.com</i>. 4 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drugs.com&rft.atitle=Nivolumab+%28Opdivo%29+Use+During+Pregnancy&rft.date=2019-11-04&rft_id=https%3A%2F%2Fwww.drugs.com%2Fpregnancy%2Fnivolumab.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-AHFS2019-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-AHFS2019_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-AHFS2019_2-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.drugs.com/monograph/nivolumab.html">"Nivolumab Monograph for Professionals"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">14 November</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drugs.com&rft.atitle=Nivolumab+Monograph+for+Professionals&rft_id=https%3A%2F%2Fwww.drugs.com%2Fmonograph%2Fnivolumab.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-UK2019-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-UK2019_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-UK2019_3-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/nivolumab">"Nivolumab (Opdivo)"</a>. <i>Cancer Research UK</i><span class="reference-accessdate">. Retrieved <span class="nowrap">15 December</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Cancer+Research+UK&rft.atitle=Nivolumab+%28Opdivo%29&rft_id=https%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Fcancer-in-general%2Ftreatment%2Fcancer-drugs%2Fdrugs%2Fnivolumab&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2016">"Prescription medicines: registration of new chemical entities in Australia, 2016"</a>. <i>Therapeutic Goods Administration (TGA)</i>. 21 June 2022<span class="reference-accessdate">. Retrieved <span class="nowrap">10 April</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Therapeutic+Goods+Administration+%28TGA%29&rft.atitle=Prescription+medicines%3A+registration+of+new+chemical+entities+in+Australia%2C+2016&rft.date=2022-06-21&rft_id=https%3A%2F%2Fwww.tga.gov.au%2Fprescription-medicines-registration-new-chemical-entities-australia-2016&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.tga.gov.au/resources/publication/publications/prescription-medicines-and-biologicals-tga-annual-summary-2017">"Prescription medicines and biologicals: TGA annual summary 2017"</a>. <i>Therapeutic Goods Administration (TGA)</i>. 21 June 2022<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Therapeutic+Goods+Administration+%28TGA%29&rft.atitle=Prescription+medicines+and+biologicals%3A+TGA+annual+summary+2017&rft.date=2022-06-21&rft_id=https%3A%2F%2Fwww.tga.gov.au%2Fresources%2Fpublication%2Fpublications%2Fprescription-medicines-and-biologicals-tga-annual-summary-2017&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1708530494939">"Regulatory Decision Summary for Opdivo"</a>. <i>Drug and Health Products Portal</i>. 29 December 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drug+and+Health+Products+Portal&rft.atitle=Regulatory+Decision+Summary+for+Opdivo&rft.date=2023-12-29&rft_id=https%3A%2F%2Fdhpp.hpfb-dgpsa.ca%2Freview-documents%2Fresource%2FRDS1708530494939&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2015-highlights.html">"Health Canada New Drug Authorizations: 2015 Highlights"</a>. <i><a href="/wiki/Health_Canada" title="Health Canada">Health Canada</a></i>. 4 May 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">7 April</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Health+Canada&rft.atitle=Health+Canada+New+Drug+Authorizations%3A+2015+Highlights&rft.date=2016-05-04&rft_id=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fservices%2Fpublications%2Fdrugs-health-products%2Fhealth-canada-new-drug-authorizations-2015-highlights.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.medicines.org.uk/emc/product/6888">"Opdivo 10 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC)"</a>. <i>(emc)</i>. 24 August 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=%28emc%29&rft.atitle=Opdivo+10+mg%2FmL+concentrate+for+solution+for+infusion+-+Summary+of+Product+Characteristics+%28SmPC%29&rft.date=2020-08-24&rft_id=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Fproduct%2F6888&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-Opdivo_FDA_label-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Opdivo_FDA_label_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-Opdivo_FDA_label_9-30"><sup><i><b>ae</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394">"Opdivo- nivolumab injection"</a>. <i>DailyMed</i>. 17 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=DailyMed&rft.atitle=Opdivo-+nivolumab+injection&rft.date=2019-12-17&rft_id=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Df570b9c4-6846-4de2-abfa-4d0a4ae4e394&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-Opdivo_EPAR-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-Opdivo_EPAR_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Opdivo_EPAR_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Opdivo_EPAR_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Opdivo_EPAR_10-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo">"Opdivo EPAR"</a>. <i><a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">European Medicines Agency</a> (EMA)</i>. 30 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">11 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=European+Medicines+Agency+%28EMA%29&rft.atitle=Opdivo+EPAR&rft.date=2020-01-30&rft_id=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fhuman%2FEPAR%2Fopdivo&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_PR_20210416-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20210416_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20210416_11-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20210416_11-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_PR_20210416_11-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_PR_20210416_11-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-initial-treatment-gastric-cancer">"FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i> (Press release). 16 April 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">16 April</span> 2021</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+Approves+First+Immunotherapy+for+Initial+Treatment+of+Gastric+Cancer&rft.date=2021-04-16&rft_id=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-immunotherapy-initial-treatment-gastric-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA_nivolumab_20210520-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_nivolumab_20210520_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_nivolumab_20210520_12-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_nivolumab_20210520_12-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-resected-esophageal-or-gej-cancer">"FDA approves nivolumab for resected esophageal or GEJ cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 20 May 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">20 May</span> 2021</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+nivolumab+for+resected+esophageal+or+GEJ+cancer&rft.date=2021-05-20&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Ffda-approves-nivolumab-resected-esophageal-or-gej-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-WHO23rd-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-WHO23rd_13-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFWorld_Health_Organization2023" class="citation book cs1"><a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (2023). <i>The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)</i>. Geneva: World Health Organization. <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://hdl.handle.net/10665%2F371090">10665/371090</a></span>. WHO/MHP/HPS/EML/2023.02.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.btitle=The+selection+and+use+of+essential+medicines+2023%3A+web+annex+A%3A+World+Health+Organization+model+list+of+essential+medicines%3A+23rd+list+%282023%29&rft.place=Geneva&rft.pub=World+Health+Organization&rft.date=2023&rft_id=info%3Ahdl%2F10665%2F371090&rft.au=World+Health+Organization&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFRajanKimHeeryGuha2016" class="citation journal cs1">Rajan A, Kim C, Heery CR, Guha U, Gulley JL (September 2016). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027703">"Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers"</a>. <i>Human Vaccines & Immunotherapeutics</i>. <b>12</b> (9): <span class="nowrap">2219–</span>31. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1080%2F21645515.2016.1175694">10.1080/21645515.2016.1175694</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027703">5027703</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27135835">27135835</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Human+Vaccines+%26+Immunotherapeutics&rft.atitle=Nivolumab%2C+anti-programmed+death-1+%28PD-1%29+monoclonal+antibody+immunotherapy%3A+Role+in+advanced+cancers&rft.volume=12&rft.issue=9&rft.pages=%3Cspan+class%3D%22nowrap%22%3E2219-%3C%2Fspan%3E31&rft.date=2016-09&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5027703%23id-name%3DPMC&rft_id=info%3Apmid%2F27135835&rft_id=info%3Adoi%2F10.1080%2F21645515.2016.1175694&rft.aulast=Rajan&rft.aufirst=A&rft.au=Kim%2C+C&rft.au=Heery%2C+CR&rft.au=Guha%2C+U&rft.au=Gulley%2C+JL&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5027703&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_PR_20201002-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20201002_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20201002_15-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20201002_15-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/news-events/press-announcements/fda-approves-drug-combination-treating-mesothelioma">"FDA Approves Drug Combination for Treating Mesothelioma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i> (Press release). 2 October 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+Approves+Drug+Combination+for+Treating+Mesothelioma&rft.date=2020-10-02&rft_id=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-drug-combination-treating-mesothelioma&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-2015revMel-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-2015revMel_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-2015revMel_16-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-2015revMel_16-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-2015revMel_16-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-2015revMel_16-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-2015revMel_16-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFJohnsonPengSosman2015" class="citation journal cs1">Johnson DB, Peng C, Sosman JA (March 2015). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346215">"Nivolumab in melanoma: latest evidence and clinical potential"</a>. <i>Therapeutic Advances in Medical Oncology</i>. <b>7</b> (2): <span class="nowrap">97–</span>106. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F1758834014567469">10.1177/1758834014567469</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346215">4346215</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25755682">25755682</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Therapeutic+Advances+in+Medical+Oncology&rft.atitle=Nivolumab+in+melanoma%3A+latest+evidence+and+clinical+potential&rft.volume=7&rft.issue=2&rft.pages=%3Cspan+class%3D%22nowrap%22%3E97-%3C%2Fspan%3E106&rft.date=2015-03&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346215%23id-name%3DPMC&rft_id=info%3Apmid%2F25755682&rft_id=info%3Adoi%2F10.1177%2F1758834014567469&rft.aulast=Johnson&rft.aufirst=DB&rft.au=Peng%2C+C&rft.au=Sosman%2C+JA&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346215&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-2015revNSCLC-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-2015revNSCLC_17-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFSundarChoBrahmerSoo2015" class="citation journal cs1">Sundar R, Cho BC, Brahmer JR, Soo RA (March 2015). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216">"Nivolumab in NSCLC: latest evidence and clinical potential"</a>. <i>Therapeutic Advances in Medical Oncology</i>. <b>7</b> (2): <span class="nowrap">85–</span>96. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F1758834014567470">10.1177/1758834014567470</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216">4346216</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25755681">25755681</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Therapeutic+Advances+in+Medical+Oncology&rft.atitle=Nivolumab+in+NSCLC%3A+latest+evidence+and+clinical+potential&rft.volume=7&rft.issue=2&rft.pages=%3Cspan+class%3D%22nowrap%22%3E85-%3C%2Fspan%3E96&rft.date=2015-03&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346216%23id-name%3DPMC&rft_id=info%3Apmid%2F25755681&rft_id=info%3Adoi%2F10.1177%2F1758834014567470&rft.aulast=Sundar&rft.aufirst=R&rft.au=Cho%2C+BC&rft.au=Brahmer%2C+JR&rft.au=Soo%2C+RA&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346216&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFBushey2017" class="citation web cs1">Bushey R (3 February 2017). <a rel="nofollow" class="external text" href="https://web.archive.org/web/20170204085528/http://www.dddmag.com/article/2017/02/opdivo-gains-fda-approval-common-bladder-cancer?et_cid=5813686&et_rid=297252576&type=headline&et_cid=5813686&et_rid=297252576&linkid=content">"Opdivo Gains FDA Approval for Common Bladder Cancer"</a>. <i>Drug Discovery & Development</i>. Archived from <a rel="nofollow" class="external text" href="http://www.dddmag.com/article/2017/02/opdivo-gains-fda-approval-common-bladder-cancer?et_cid=5813686&et_rid=297252576&type=headline&et_cid=5813686&et_rid=297252576&linkid=content">the original</a> on 4 February 2017.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drug+Discovery+%26+Development&rft.atitle=Opdivo+Gains+FDA+Approval+for+Common+Bladder+Cancer&rft.date=2017-02-03&rft.aulast=Bushey&rft.aufirst=R&rft_id=http%3A%2F%2Fwww.dddmag.com%2Farticle%2F2017%2F02%2Fopdivo-gains-fda-approval-common-bladder-cancer%3Fet_cid%3D5813686%26et_rid%3D297252576%26type%3Dheadline%26et_cid%3D5813686%26et_rid%3D297252576%26linkid%3Dcontent&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-nivolumab-adjuvant-treatment-melanoma">"FDA grants regular approval to nivolumab for adjuvant treatment of melanoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 20 December 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+grants+regular+approval+to+nivolumab+for+adjuvant+treatment+of+melanoma&rft.date=2017-12-20&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-grants-regular-approval-nivolumab-adjuvant-treatment-melanoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma">"FDA approves nivolumab for adjuvant treatment of urothelial carcinoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 20 August 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">20 August</span> 2021</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+nivolumab+for+adjuvant+treatment+of+urothelial+carcinoma&rft.date=2021-08-20&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdivo-combination-chemotherapy-and-opdivo-combination-yervoy-first-line-esophageal">"FDA approves Opdivo"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 31 May 2022<span class="reference-accessdate">. Retrieved <span class="nowrap">31 May</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+Opdivo&rft.date=2022-05-31&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-opdivo-combination-chemotherapy-and-opdivo-combination-yervoy-first-line-esophageal&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-opdualag-melanoma-lag-3">"FDA approves nivolumab for adjuvant treatment of urothelial carcinoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 6 April 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">6 April</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+nivolumab+for+adjuvant+treatment+of+urothelial+carcinoma&rft.date=2023-04-06&rft_id=https%3A%2F%2Fwww.cancer.gov%2Fnews-events%2Fcancer-currents-blog%2F2022%2Ffda-opdualag-melanoma-lag-3&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA_20240306-23"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_20240306_23-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_20240306_23-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_20240306_23-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_20240306_23-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_20240306_23-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_20240306_23-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial">"FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 6 March 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">9 March</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+nivolumab+in+combination+with+cisplatin+and+gemcitabine+for+unresectable+or+metastatic+urothelial+carcinoma&rft.date=2024-03-06&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://pmlive.com/pharma_news/bristol-myers-squibbs-opdivo-combination-receives-fda-approval-for-urothelial-carcinoma/">"Bristol Myers Squibb's Opdivo combination receives FDA approval for urothelial carcinoma"</a>. <i>PMLiVE</i>. 8 March 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">8 March</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=PMLiVE&rft.atitle=Bristol+Myers+Squibb%27s+Opdivo+combination+receives+FDA+approval+for+urothelial+carcinoma&rft.date=2024-03-08&rft_id=https%3A%2F%2Fpmlive.com%2Fpharma_news%2Fbristol-myers-squibbs-opdivo-combination-receives-fda-approval-for-urothelial-carcinoma%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_PR_20241004-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDA_PR_20241004_25-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/news-events/press-announcements/fda-roundup-october-4-2024">"FDA Roundup: October 4, 2024"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i> (Press release). 4 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">8 October</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+Roundup%3A+October+4%2C+2024&rft.date=2024-10-04&rft_id=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-roundup-october-4-2024&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-nivolumab-resectable-non-small-cell-lung-cancer">"FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 3 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+neoadjuvant%2Fadjuvant+nivolumab+for+resectable+non-small+cell+lung+cancer&rft.date=2024-10-03&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-neoadjuvantadjuvant-nivolumab-resectable-non-small-cell-lung-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-DeFilette2019-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-DeFilette2019_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DeFilette2019_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFde_FiletteAndreescuCoolsBravenboer2019" class="citation journal cs1">de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (March 2019). <a rel="nofollow" class="external text" href="https://doi.org/10.1055%2Fa-0843-3366">"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors"</a>. <i>Hormone and Metabolic Research</i>. <b>51</b> (3): <span class="nowrap">145–</span>156. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1055%2Fa-0843-3366">10.1055/a-0843-3366</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30861560">30861560</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Hormone+and+Metabolic+Research&rft.atitle=A+Systematic+Review+and+Meta-Analysis+of+Endocrine-Related+Adverse+Events+Associated+with+Immune+Checkpoint+Inhibitors&rft.volume=51&rft.issue=3&rft.pages=%3Cspan+class%3D%22nowrap%22%3E145-%3C%2Fspan%3E156&rft.date=2019-03&rft_id=info%3Adoi%2F10.1055%2Fa-0843-3366&rft_id=info%3Apmid%2F30861560&rft.aulast=de+Filette&rft.aufirst=J&rft.au=Andreescu%2C+CE&rft.au=Cools%2C+F&rft.au=Bravenboer%2C+B&rft.au=Velkeniers%2C+B&rft_id=https%3A%2F%2Fdoi.org%2F10.1055%252Fa-0843-3366&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-Pardoll2012-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-Pardoll2012_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Pardoll2012_28-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Pardoll2012_28-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFPardoll2012" class="citation journal cs1">Pardoll DM (March 2012). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023">"The blockade of immune checkpoints in cancer immunotherapy"</a>. <i>Nature Reviews. Cancer</i>. <b>12</b> (4): <span class="nowrap">252–</span>64. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fnrc3239">10.1038/nrc3239</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023">4856023</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/22437870">22437870</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Nature+Reviews.+Cancer&rft.atitle=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&rft.volume=12&rft.issue=4&rft.pages=%3Cspan+class%3D%22nowrap%22%3E252-%3C%2Fspan%3E64&rft.date=2012-03&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4856023%23id-name%3DPMC&rft_id=info%3Apmid%2F22437870&rft_id=info%3Adoi%2F10.1038%2Fnrc3239&rft.aulast=Pardoll&rft.aufirst=DM&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4856023&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-:0-29"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_29-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_29-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:0_29-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:0_29-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFSynTengMokSoo2017" class="citation journal cs1">Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". <i>The Lancet. Oncology</i>. <b>18</b> (12): <span class="nowrap">e731 –</span> <span class="nowrap">e741</span>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1">10.1016/s1470-2045(17)30607-1</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29208439">29208439</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+Lancet.+Oncology&rft.atitle=De-novo+and+acquired+resistance+to+immune+checkpoint+targeting&rft.volume=18&rft.issue=12&rft.pages=%3Cspan+class%3D%22nowrap%22%3Ee731+-%3C%2Fspan%3E+%3Cspan+class%3D%22nowrap%22%3Ee741%3C%2Fspan%3E&rft.date=2017-12&rft_id=info%3Adoi%2F10.1016%2Fs1470-2045%2817%2930607-1&rft_id=info%3Apmid%2F29208439&rft.aulast=Syn&rft.aufirst=NL&rft.au=Teng%2C+MW&rft.au=Mok%2C+TS&rft.au=Soo%2C+RA&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-INN-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-INN_30-0">^</a></b></span> <span class="reference-text">WHO Drug Information, Vol. 26, No. 2, 2012. <a rel="nofollow" class="external text" href="https://www.prescrire.org/Docu/DOCSDCI/WHO_INN_ProposedList107.pdf">Proposed INN List 107</a></span> </li> <li id="cite_note-auto-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-auto_31-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFWangThudiumHanWang2014" class="citation journal cs1">Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. (September 2014). <a rel="nofollow" class="external text" href="https://doi.org/10.1158%2F2326-6066.CIR-14-0040">"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates"</a>. <i>Cancer Immunology Research</i>. <b>2</b> (9): <span class="nowrap">846–</span>56. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1158%2F2326-6066.CIR-14-0040">10.1158/2326-6066.CIR-14-0040</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/24872026">24872026</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Cancer+Immunology+Research&rft.atitle=In+vitro+characterization+of+the+anti-PD-1+antibody+nivolumab%2C+BMS-936558%2C+and+in+vivo+toxicology+in+non-human+primates&rft.volume=2&rft.issue=9&rft.pages=%3Cspan+class%3D%22nowrap%22%3E846-%3C%2Fspan%3E56&rft.date=2014-09&rft_id=info%3Adoi%2F10.1158%2F2326-6066.CIR-14-0040&rft_id=info%3Apmid%2F24872026&rft.aulast=Wang&rft.aufirst=C&rft.au=Thudium%2C+KB&rft.au=Han%2C+M&rft.au=Wang%2C+XT&rft.au=Huang%2C+H&rft.au=Feingersh%2C+D&rft.au=Garcia%2C+C&rft.au=Wu%2C+Y&rft.au=Kuhne%2C+M&rft.au=Srinivasan%2C+M&rft.au=Singh%2C+S&rft.au=Wong%2C+S&rft.au=Garner%2C+N&rft.au=Leblanc%2C+H&rft.au=Bunch%2C+RT&rft.au=Blanset%2C+D&rft.au=Selby%2C+MJ&rft.au=Korman%2C+AJ&rft_id=https%3A%2F%2Fdoi.org%2F10.1158%252F2326-6066.CIR-14-0040&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFAllison2009" class="citation journal cs1">Allison M (September 2009). "Bristol-Myers Squibb swallows last of antibody pioneers". <i>Nature Biotechnology</i>. <b>27</b> (9): <span class="nowrap">781–</span>3. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fnbt0909-781">10.1038/nbt0909-781</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/19741612">19741612</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:205270797">205270797</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Nature+Biotechnology&rft.atitle=Bristol-Myers+Squibb+swallows+last+of+antibody+pioneers&rft.volume=27&rft.issue=9&rft.pages=%3Cspan+class%3D%22nowrap%22%3E781-%3C%2Fspan%3E3&rft.date=2009-09&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205270797%23id-name%3DS2CID&rft_id=info%3Apmid%2F19741612&rft_id=info%3Adoi%2F10.1038%2Fnbt0909-781&rft.aulast=Allison&rft.aufirst=M&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFCarroll2009" class="citation web cs1">Carroll J (23 July 2009). <a rel="nofollow" class="external text" href="https://www.fiercebiotech.com/biotech/bristol-myers-to-buy-medarex-for-2-1b">"Bristol-Myers to buy Medarex for $2.1B"</a>. <i>Fierce Biotech</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Fierce+Biotech&rft.atitle=Bristol-Myers+to+buy+Medarex+for+%242.1B&rft.date=2009-07-23&rft.aulast=Carroll&rft.aufirst=John&rft_id=https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fbristol-myers-to-buy-medarex-for-2-1b&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFCarroll2014" class="citation web cs1">Carroll J (7 July 2014). <a rel="nofollow" class="external text" href="https://www.fiercebiotech.com/biotech/anti-pd-1-cancer-star-nivolumab-wins-world-s-first-regulatory-approval">"Anti-PD-1 cancer star nivolumab wins world's first regulatory approval"</a>. <i>Fierce Biotech</i><span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Fierce+Biotech&rft.atitle=Anti-PD-1+cancer+star+nivolumab+wins+world%27s+first+regulatory+approval&rft.date=2014-07-07&rft.aulast=Carroll&rft.aufirst=John&rft_id=https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fanti-pd-1-cancer-star-nivolumab-wins-world-s-first-regulatory-approval&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170213201355/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm">"FDA approves Opdivo for advanced melanoma"</a> (Press release). U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA). 22 December 2014. Archived from <a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm">the original</a> on 13 February 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">16 December</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+Opdivo+for+advanced+melanoma&rft.pub=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.date=2014-12-22&rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm427716.htm&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.ema.europa.eu/en/news/new-treatment-advanced-melanoma">"New treatment for advanced melanoma"</a>. <i><a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">European Medicines Agency</a> (EMA)</i> (Press release). 24 April 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">11 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=New+treatment+for+advanced+melanoma&rft.date=2015-04-24&rft_id=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fnews%2Fnew-treatment-advanced-melanoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA2015-Mar-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDA2015-Mar_37-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20150305125132/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm">"FDA expands approved use of Opdivo to treat lung cancer"</a> (Press release). U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA). Archived from <a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm">the original</a> on 5 March 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">4 March</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+expands+approved+use+of+Opdivo+to+treat+lung+cancer&rft.pub=U.S.+Food+and+Drug+Administration+%28FDA%29&rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm436534.htm&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-FDApress2015renal-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDApress2015renal_38-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20180125101444/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm">"FDA approves Opdivo to treat advanced form of kidney cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i> (Press release). 23 November 2015. Archived from <a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm">the original</a> on 25 January 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+Opdivo+to+treat+advanced+form+of+kidney+cancer&rft.date=2015-11-23&rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm473971.htm&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-opdivo-hodgkin-lymphoma">"Nivolumab (Opdivo) for Hodgkin Lymphoma"</a>. U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA). 17 May 2016.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Nivolumab+%28Opdivo%29+for+Hodgkin+Lymphoma&rft.pub=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.date=2016-05-17&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Fnivolumab-opdivo-hodgkin-lymphoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-nivolumab-adjuvant-treatment-melanoma">"FDA grants regular approval to nivolumab for adjuvant treatment of melanoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 21 December 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">12 April</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+grants+regular+approval+to+nivolumab+for+adjuvant+treatment+of+melanoma&rft.date=2017-12-21&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-grants-regular-approval-nivolumab-adjuvant-treatment-melanoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell">"FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">20 April</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+nivolumab+plus+ipilimumab+combination+for+intermediate+or+poor-risk+advanced+renal+cell+carcinoma&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fiercepharma.com/pharma-asia/opdivo-for-lung-cancer-first-i-o-therapy-approved-china">"Bristol-Myers' Opdivo ushers in a new era as the first I-O therapy approved in China | FiercePharma"</a>. <i>www.fiercepharma.com</i>. 15 June 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">19 June</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=www.fiercepharma.com&rft.atitle=Bristol-Myers%27+Opdivo+ushers+in+a+new+era+as+the+first+I-O+therapy+approved+in+China+%7C+FiercePharma&rft.date=2018-06-15&rft_id=https%3A%2F%2Fwww.fiercepharma.com%2Fpharma-asia%2Fopdivo-for-lung-cancer-first-i-o-therapy-approved-china&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFCaponnettoDraghiBorchNuti2018" class="citation journal cs1">Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, et al. (May 2018). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028279">"Cancer immunotherapy in patients with brain metastases"</a>. <i>Cancer Immunology, Immunotherapy</i>. <b>67</b> (5): <span class="nowrap">703–</span>711. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs00262-018-2146-8">10.1007/s00262-018-2146-8</a>. <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://hdl.handle.net/11573%2F1298742">11573/1298742</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028279">11028279</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29520474">29520474</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:3782427">3782427</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Cancer+Immunology%2C+Immunotherapy&rft.atitle=Cancer+immunotherapy+in+patients+with+brain+metastases&rft.volume=67&rft.issue=5&rft.pages=%3Cspan+class%3D%22nowrap%22%3E703-%3C%2Fspan%3E711&rft.date=2018-05&rft_id=info%3Ahdl%2F11573%2F1298742&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A3782427%23id-name%3DS2CID&rft_id=info%3Adoi%2F10.1007%2Fs00262-018-2146-8&rft_id=info%3Apmid%2F29520474&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11028279%23id-name%3DPMC&rft.aulast=Caponnetto&rft.aufirst=S&rft.au=Draghi%2C+A&rft.au=Borch%2C+TH&rft.au=Nuti%2C+M&rft.au=Cortesi%2C+E&rft.au=Svane%2C+IM&rft.au=Donia%2C+M&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11028279&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFDoniaPedersenSvane2017" class="citation journal cs1">Donia M, Pedersen M, Svane IM (April 2017). "Cancer immunotherapy in patients with preexisting autoimmune disorders". <i>Seminars in Immunopathology</i>. <b>39</b> (3): <span class="nowrap">333–</span>337. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs00281-016-0595-8">10.1007/s00281-016-0595-8</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27730287">27730287</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:3387103">3387103</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Seminars+in+Immunopathology&rft.atitle=Cancer+immunotherapy+in+patients+with+preexisting+autoimmune+disorders&rft.volume=39&rft.issue=3&rft.pages=%3Cspan+class%3D%22nowrap%22%3E333-%3C%2Fspan%3E337&rft.date=2017-04&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A3387103%23id-name%3DS2CID&rft_id=info%3Apmid%2F27730287&rft_id=info%3Adoi%2F10.1007%2Fs00281-016-0595-8&rft.aulast=Donia&rft.aufirst=M&rft.au=Pedersen%2C+M&rft.au=Svane%2C+IM&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-Science2015rev-45"><span class="mw-cite-backlink">^ <a href="#cite_ref-Science2015rev_45-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Science2015rev_45-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Science2015rev_45-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFSharmaAllison2015" class="citation journal cs1">Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". <i>Science</i>. <b>348</b> (6230): <span class="nowrap">56–</span>61. <a href="/wiki/Bibcode_(identifier)" class="mw-redirect" title="Bibcode (identifier)">Bibcode</a>:<a rel="nofollow" class="external text" href="https://ui.adsabs.harvard.edu/abs/2015Sci...348...56S">2015Sci...348...56S</a>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1126%2Fscience.aaa8172">10.1126/science.aaa8172</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25838373">25838373</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:4608450">4608450</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Science&rft.atitle=The+future+of+immune+checkpoint+therapy&rft.volume=348&rft.issue=6230&rft.pages=%3Cspan+class%3D%22nowrap%22%3E56-%3C%2Fspan%3E61&rft.date=2015-04&rft_id=info%3Adoi%2F10.1126%2Fscience.aaa8172&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A4608450%23id-name%3DS2CID&rft_id=info%3Apmid%2F25838373&rft_id=info%3Abibcode%2F2015Sci...348...56S&rft.aulast=Sharma&rft.aufirst=P&rft.au=Allison%2C+JP&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFGoldkuhleDimakiGartlehnerMonsef2018" class="citation journal cs1">Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, et al. (Cochrane Haematological Malignancies Group) (July 2018). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513229">"Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>2018</b> (7): CD012556. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD012556.pub2">10.1002/14651858.CD012556.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513229">6513229</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30001476">30001476</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&rft.atitle=Nivolumab+for+adults+with+Hodgkin%27s+lymphoma+%28a+rapid+review+using+the+software+RobotReviewer%29&rft.volume=2018&rft.issue=7&rft.pages=CD012556&rft.date=2018-07&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6513229%23id-name%3DPMC&rft_id=info%3Apmid%2F30001476&rft_id=info%3Adoi%2F10.1002%2F14651858.CD012556.pub2&rft.aulast=Goldkuhle&rft.aufirst=M&rft.au=Dimaki%2C+M&rft.au=Gartlehner%2C+G&rft.au=Monsef%2C+I&rft.au=Dahm%2C+P&rft.au=Glossmann%2C+JP&rft.au=Engert%2C+A&rft.au=von+Tresckow%2C+B&rft.au=Skoetz%2C+N&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6513229&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFLoftusRockoffSteele2016" class="citation news cs1">Loftus P, Rockoff JD, Steele A (5 August 2016). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/bristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926">"Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study"</a>. <i><a href="/wiki/The_Wall_Street_Journal" title="The Wall Street Journal">The Wall Street Journal</a></i>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" class="external text" href="https://search.worldcat.org/issn/0099-9660">0099-9660</a><span class="reference-accessdate">. Retrieved <span class="nowrap">21 August</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+Wall+Street+Journal&rft.atitle=Bristol+Myers%3A+Opdivo+Failed+to+Meet+Endpoint+in+Key+Lung-Cancer+Study&rft.date=2016-08-05&rft.issn=0099-9660&rft.aulast=Loftus&rft.aufirst=P&rft.au=Rockoff%2C+JD&rft.au=Steele%2C+A&rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fbristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFErman2019" class="citation news cs1">Erman M (24 January 2019). <a rel="nofollow" class="external text" href="https://finance.yahoo.com/news/bristol-myers-opdivo-lung-cancer-172155354.html">"Bristol-Myers has Opdivo lung cancer setback as sales beat estimates"</a>. <a href="/wiki/Reuters" title="Reuters">Reuters</a><span class="reference-accessdate">. Retrieved <span class="nowrap">24 January</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bristol-Myers+has+Opdivo+lung+cancer+setback+as+sales+beat+estimates&rft.date=2019-01-24&rft.aulast=Erman&rft.aufirst=M&rft_id=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fbristol-myers-opdivo-lung-cancer-172155354.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-Waterhouse_2018-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-Waterhouse_2018_49-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFWaterhouseHornReynoldsSpigel2018" class="citation journal cs1">Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, et al. (April 2018). "Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153". <i>Cancer Chemotherapy and Pharmacology</i>. <b>81</b> (4): <span class="nowrap">679–</span>686. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs00280-018-3527-6">10.1007/s00280-018-3527-6</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29442139">29442139</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:3906670">3906670</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Cancer+Chemotherapy+and+Pharmacology&rft.atitle=Safety+profile+of+nivolumab+administered+as+30-min+infusion%3A+analysis+of+data+from+CheckMate+153&rft.volume=81&rft.issue=4&rft.pages=%3Cspan+class%3D%22nowrap%22%3E679-%3C%2Fspan%3E686&rft.date=2018-04&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A3906670%23id-name%3DS2CID&rft_id=info%3Apmid%2F29442139&rft_id=info%3Adoi%2F10.1007%2Fs00280-018-3527-6&rft.aulast=Waterhouse&rft.aufirst=D&rft.au=Horn%2C+L&rft.au=Reynolds%2C+C&rft.au=Spigel%2C+D&rft.au=Chandler%2C+J&rft.au=Mekhail%2C+T&rft.au=Mohamed%2C+M&rft.au=Creelan%2C+B&rft.au=Blankstein%2C+KB&rft.au=Nikolinakos%2C+P&rft.au=McCleod%2C+MJ&rft.au=Li%2C+A&rft.au=Oukessou%2C+A&rft.au=Agrawal%2C+S&rft.au=Aanur%2C+N&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-:1-50"><span class="mw-cite-backlink">^ <a href="#cite_ref-:1_50-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:1_50-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:1_50-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:1_50-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:1_50-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFHellmannPaz-AresBernabe_CaroZurawski2019" class="citation journal cs1">Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. (November 2019). <a rel="nofollow" class="external text" href="https://doi.org/10.1056%2FNEJMoa1910231">"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer"</a>. <i>The New England Journal of Medicine</i>. <b>381</b> (21): <span class="nowrap">2020–</span>2031. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1056%2FNEJMoa1910231">10.1056/NEJMoa1910231</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/31562796">31562796</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+New+England+Journal+of+Medicine&rft.atitle=Nivolumab+plus+Ipilimumab+in+Advanced+Non-Small-Cell+Lung+Cancer&rft.volume=381&rft.issue=21&rft.pages=%3Cspan+class%3D%22nowrap%22%3E2020-%3C%2Fspan%3E2031&rft.date=2019-11&rft_id=info%3Adoi%2F10.1056%2FNEJMoa1910231&rft_id=info%3Apmid%2F31562796&rft.aulast=Hellmann&rft.aufirst=MD&rft.au=Paz-Ares%2C+L&rft.au=Bernabe+Caro%2C+R&rft.au=Zurawski%2C+B&rft.au=Kim%2C+SW&rft.au=Carcereny+Costa%2C+E&rft.au=Park%2C+K&rft.au=Alexandru%2C+A&rft.au=Lupinacci%2C+L&rft.au=de+la+Mora+Jimenez%2C+E&rft.au=Sakai%2C+H&rft.au=Albert%2C+I&rft.au=Vergnenegre%2C+A&rft.au=Peters%2C+S&rft.au=Syrigos%2C+K&rft.au=Barlesi%2C+F&rft.au=Reck%2C+M&rft.au=Borghaei%2C+H&rft.au=Brahmer%2C+JR&rft.au=O%27Byrne%2C+KJ&rft.au=Geese%2C+WJ&rft.au=Bhagavatheeswaran%2C+P&rft.au=Rabindran%2C+SK&rft.au=Kasinathan%2C+RS&rft.au=Nathan%2C+FE&rft.au=Ramalingam%2C+SS&rft_id=https%3A%2F%2Fdoi.org%2F10.1056%252FNEJMoa1910231&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-:2-51"><span class="mw-cite-backlink">^ <a href="#cite_ref-:2_51-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:2_51-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:2_51-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:2_51-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:2_51-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFNasserGorenbergAgbarya2020" class="citation journal cs1">Nasser NJ, Gorenberg M, Agbarya A (November 2020). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295">"First line Immunotherapy for Non-Small Cell Lung Cancer"</a>. <i>Pharmaceuticals</i>. <b>13</b> (11): 373. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.3390%2Fph13110373">10.3390/ph13110373</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295">7695295</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/33171686">33171686</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Pharmaceuticals&rft.atitle=First+line+Immunotherapy+for+Non-Small+Cell+Lung+Cancer&rft.volume=13&rft.issue=11&rft.pages=373&rft.date=2020-11&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7695295%23id-name%3DPMC&rft_id=info%3Apmid%2F33171686&rft_id=info%3Adoi%2F10.3390%2Fph13110373&rft.aulast=Nasser&rft.aufirst=NJ&rft.au=Gorenberg%2C+M&rft.au=Agbarya%2C+A&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7695295&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-auto1-52"><span class="mw-cite-backlink">^ <a href="#cite_ref-auto1_52-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-auto1_52-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://clinicaltrials.gov/ct2/show/NCT03215706">"A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer"</a>. 11 November 2022.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=A+Phase+3%2C+Randomized+Study+of+Nivolumab+Plus+Ipilimumab+in+Combination+With+Chemotherapy+vs+Chemotherapy+Alone+as+First+Line+Therapy+in+Stage+IV+Non-Small+Cell+Lung+Cancer&rft.date=2022-11-11&rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03215706&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://news.bms.com/news/details/2023/Four-Year-Outcomes-from-Phase-3-CheckMate--9LA-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx">"Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer"</a>. <i>Bristol Myers Squibb</i> (Press release)<span class="reference-accessdate">. Retrieved <span class="nowrap">5 June</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Four-Year+Outcomes+from+Phase+3+CheckMate+-9LA+Trial+Show+Durable%2C+Long-Term+Survival+with+Opdivo+%28nivolumab%29+Plus+Yervoy+%28ipilimumab%29+with+Two+Cycles+of+Chemotherapy+for+Patients+with+Metastatic+Non-Small+Cell+Lung+Cancer&rft_id=https%3A%2F%2Fnews.bms.com%2Fnews%2Fdetails%2F2023%2FFour-Year-Outcomes-from-Phase-3-CheckMate--9LA-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer%2Fdefault.aspx&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite id="CITEREFDongStromeSalomaoTamura2002" class="citation journal cs1">Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. (August 2002). "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion". <i>Nature Medicine</i>. <b>8</b> (8): <span class="nowrap">793–</span>800. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fnm730">10.1038/nm730</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/12091876">12091876</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:27694471">27694471</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Nature+Medicine&rft.atitle=Tumor-associated+B7-H1+promotes+T-cell+apoptosis%3A+a+potential+mechanism+of+immune+evasion&rft.volume=8&rft.issue=8&rft.pages=%3Cspan+class%3D%22nowrap%22%3E793-%3C%2Fspan%3E800&rft.date=2002-08&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A27694471%23id-name%3DS2CID&rft_id=info%3Apmid%2F12091876&rft_id=info%3Adoi%2F10.1038%2Fnm730&rft.aulast=Dong&rft.aufirst=H&rft.au=Strome%2C+SE&rft.au=Salomao%2C+DR&rft.au=Tamura%2C+H&rft.au=Hirano%2C+F&rft.au=Flies%2C+DB&rft.au=Roche%2C+PC&rft.au=Lu%2C+J&rft.au=Zhu%2C+G&rft.au=Tamada%2C+K&rft.au=Lennon%2C+VA&rft.au=Celis%2C+E&rft.au=Chen%2C+L&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-:3-55"><span class="mw-cite-backlink">^ <a href="#cite_ref-:3_55-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:3_55-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001230-34/IT">"CA209-76K"</a>. <i>EU Clinical Trials Register</i><span class="reference-accessdate">. Retrieved <span class="nowrap">20 October</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=EU+Clinical+Trials+Register&rft.atitle=CA209-76K&rft_id=https%3A%2F%2Fwww.clinicaltrialsregister.eu%2Fctr-search%2Ftrial%2F2019-001230-34%2FIT&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Announces-Adjuvant-Treatment-with-Opdivo-nivolumab-Demonstrated-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Recurrence-Free-Survival-RFS-in-Patients-with-Stage-IIBC-Melanoma-in-the-CheckMate--76K-Trial/default.aspx">"Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial"</a>. <i>Bristol Myers Squibb</i> (Press release)<span class="reference-accessdate">. Retrieved <span class="nowrap">20 October</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Bristol+Myers+Squibb+Announces+Adjuvant+Treatment+with+Opdivo+%28nivolumab%29+Demonstrated+Statistically+Significant+and+Clinically+Meaningful+Improvement+in+Recurrence-Free+Survival+%28RFS%29+in+Patients+with+Stage+IIB%2FC+Melanoma+in+the+CheckMate+-76K+Trial&rft_id=https%3A%2F%2Fnews.bms.com%2Fnews%2Fdetails%2F2022%2FBristol-Myers-Squibb-Announces-Adjuvant-Treatment-with-Opdivo-nivolumab-Demonstrated-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Recurrence-Free-Survival-RFS-in-Patients-with-Stage-IIBC-Melanoma-in-the-CheckMate--76K-Trial%2Fdefault.aspx&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> <li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02632409">NCT02632409</a></i> for "A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span> </li> <li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.pmlive.com/pharma_news/bms_reports_positive_three-year_results_for_opdivo_to_treat_bladder_cancer_1488310">"BMS reports positive three-year results for Opdivo to treat bladder cancer"</a>. <i>PMLive</i>. 21 February 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">22 February</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=PMLive&rft.atitle=BMS+reports+positive+three-year+results+for+Opdivo+to+treat+bladder+cancer&rft.date=2023-02-21&rft_id=https%3A%2F%2Fwww.pmlive.com%2Fpharma_news%2Fbms_reports_positive_three-year_results_for_opdivo_to_treat_bladder_cancer_1488310&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></span> </li> </ol></div></div> <div class="mw-heading mw-heading2"><h2 id="External_links">External links</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&action=edit&section=16" title="Edit section: External links"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nivolumab">"Nivolumab"</a>. <i>NCI Drug Dictionary</i>. National Cancer Institute.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=NCI+Drug+Dictionary&rft.atitle=Nivolumab&rft_id=https%3A%2F%2Fwww.cancer.gov%2Fpublications%2Fdictionaries%2Fcancer-drug%2Fdef%2Fnivolumab&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222" /><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab">"Nivolumab"</a>. <i>National Cancer Institute</i>. 7 January 2015.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=National+Cancer+Institute&rft.atitle=Nivolumab&rft.date=2015-01-07&rft_id=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fdrugs%2Fnivolumab&rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01721746">NCT01721746</a></i> for "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01721772">NCT01721772</a></i> for "Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01844505">NCT01844505</a></i> for "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02388906">NCT02388906</a></i> for "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02477826">NCT02477826</a></i> for "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT03215706">NCT03215706</a></i> for "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01642004">NCT01642004</a></i> for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01673867">NCT01673867</a></i> for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02899299">NCT02899299</a></i> for "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02231749">NCT02231749</a></i> for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT03141177">NCT03141177</a></i> for "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01668784">NCT01668784</a></i> for "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02181738">NCT02181738</a></i> for "Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01592370">NCT01592370</a></i> for "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02105636">NCT02105636</a></i> for "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02387996">NCT02387996</a></i> for "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02060188">NCT02060188</a></i> for "An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01658878">NCT01658878</a></i> for "An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02743494">NCT02743494</a></i> for "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02569242">NCT02569242</a></i> for "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02872116">NCT02872116</a></i> for "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02632409">NCT02632409</a></i> for "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li></ul> <div class="navbox-styles"><style data-mw-deduplicate="TemplateStyles:r1129693374">.mw-parser-output .hlist dl,.mw-parser-output .hlist ol,.mw-parser-output .hlist ul{margin:0;padding:0}.mw-parser-output .hlist dd,.mw-parser-output .hlist dt,.mw-parser-output .hlist li{margin:0;display:inline}.mw-parser-output .hlist.inline,.mw-parser-output .hlist.inline dl,.mw-parser-output .hlist.inline ol,.mw-parser-output .hlist.inline ul,.mw-parser-output .hlist dl dl,.mw-parser-output .hlist dl ol,.mw-parser-output .hlist dl ul,.mw-parser-output .hlist ol dl,.mw-parser-output .hlist ol ol,.mw-parser-output .hlist ol ul,.mw-parser-output .hlist ul dl,.mw-parser-output .hlist ul ol,.mw-parser-output .hlist ul ul{display:inline}.mw-parser-output .hlist .mw-empty-li{display:none}.mw-parser-output .hlist dt::after{content:": "}.mw-parser-output .hlist dd::after,.mw-parser-output .hlist li::after{content:" · ";font-weight:bold}.mw-parser-output .hlist dd:last-child::after,.mw-parser-output .hlist dt:last-child::after,.mw-parser-output .hlist li:last-child::after{content:none}.mw-parser-output .hlist dd dd:first-child::before,.mw-parser-output .hlist dd dt:first-child::before,.mw-parser-output .hlist dd li:first-child::before,.mw-parser-output .hlist dt dd:first-child::before,.mw-parser-output .hlist dt dt:first-child::before,.mw-parser-output .hlist dt li:first-child::before,.mw-parser-output .hlist li dd:first-child::before,.mw-parser-output .hlist li dt:first-child::before,.mw-parser-output .hlist li li:first-child::before{content:" (";font-weight:normal}.mw-parser-output .hlist dd dd:last-child::after,.mw-parser-output .hlist dd dt:last-child::after,.mw-parser-output .hlist dd li:last-child::after,.mw-parser-output .hlist dt dd:last-child::after,.mw-parser-output .hlist dt dt:last-child::after,.mw-parser-output .hlist dt li:last-child::after,.mw-parser-output .hlist li dd:last-child::after,.mw-parser-output .hlist li dt:last-child::after,.mw-parser-output .hlist li li:last-child::after{content:")";font-weight:normal}.mw-parser-output .hlist ol{counter-reset:listitem}.mw-parser-output .hlist ol>li{counter-increment:listitem}.mw-parser-output .hlist ol>li::before{content:" "counter(listitem)"\a0 "}.mw-parser-output .hlist dd ol>li:first-child::before,.mw-parser-output .hlist dt ol>li:first-child::before,.mw-parser-output .hlist li ol>li:first-child::before{content:" ("counter(listitem)"\a0 "}</style><style data-mw-deduplicate="TemplateStyles:r1236075235">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}body.skin--responsive .mw-parser-output .navbox-image img{max-width:none!important}@media print{body.ns-0 .mw-parser-output .navbox{display:none!important}}</style></div><div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)227" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><style data-mw-deduplicate="TemplateStyles:r1239400231">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}html.skin-theme-clientpref-night .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}@media(prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}}@media print{.mw-parser-output .navbar{display:none!important}}</style><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Targeted_cancer_therapeutic_agents" title="Template:Targeted cancer therapeutic agents"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Targeted_cancer_therapeutic_agents" title="Template talk:Targeted cancer therapeutic agents"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Targeted_cancer_therapeutic_agents" title="Special:EditPage/Template:Targeted cancer therapeutic agents"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)227" style="font-size:114%;margin:0 4em"><a href="/wiki/Targeted_cancer_therapy" class="mw-redirect" title="Targeted cancer therapy">Targeted cancer therapy</a> / <a href="/wiki/Antineoplastic" class="mw-redirect" title="Antineoplastic">antineoplastic agents</a> (<a href="/wiki/ATC_code_L01" title="ATC code L01">L01</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Cancer_immunotherapy" title="Cancer immunotherapy">CI</a> <a href="/wiki/Monoclonal_antibody_therapy" title="Monoclonal antibody therapy">monoclonal antibodies</a> ("-mab")</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">Receptor tyrosine kinase</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/ErbB" title="ErbB">ErbB</a>: <i><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">HER1/EGFR</a></i> (<a href="/wiki/Cetuximab" title="Cetuximab">Cetuximab</a></li> <li><a href="/wiki/Panitumumab" title="Panitumumab">Panitumumab</a>)</li> <li><i><a href="/wiki/HER2/neu" class="mw-redirect" title="HER2/neu">HER2/neu</a></i> (<a href="/wiki/Pertuzumab" title="Pertuzumab">Pertuzumab</a></li> <li><a href="/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (<a href="/wiki/Trastuzumab/hyaluronidase" title="Trastuzumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Trastuzumab_emtansine" title="Trastuzumab emtansine">Trastuzumab emtansine</a></li> <li><a href="/wiki/Trastuzumab_deruxtecan" title="Trastuzumab deruxtecan">Trastuzumab deruxtecan</a></li> <li><a href="/wiki/Zanidatamab" title="Zanidatamab">Zanidatamab</a> )</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/EpCAM" class="mw-redirect" title="EpCAM">EpCAM</a></i> (<a href="/wiki/Catumaxomab" title="Catumaxomab">Catumaxomab</a></li> <li><a href="/wiki/Edrecolomab" title="Edrecolomab">Edrecolomab</a>)</li> <li><i><a href="/wiki/Vascular_endothelial_growth_factor_A" title="Vascular endothelial growth factor A">VEGF-A</a></i> (<a href="/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Leukemia" title="Leukemia">Leukemia</a>/<a href="/wiki/Lymphoma" title="Lymphoma">lymphoma</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Lymphatic_system" title="Lymphatic system">lymphoid</a>: <i><a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a></i> (<a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a>, <a href="/wiki/Elranatamab" title="Elranatamab">Elranatamab</a>, <a href="/wiki/Mosunetuzumab" title="Mosunetuzumab">Mosunetuzumab</a>), <i><a href="/wiki/CD20" title="CD20">CD20</a></i> (<a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a></li> <li><a href="/wiki/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li> <li><a href="/wiki/Mosunetuzumab" title="Mosunetuzumab">Mosunetuzumab</a></li> <li><a href="/wiki/Obinutuzumab" title="Obinutuzumab">Obinutuzumab</a></li> <li><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a></li> <li><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a></li> <li><a href="/wiki/Tositumomab" title="Tositumomab">Tositumomab</a>), <i><a href="/wiki/CD30" title="CD30">CD30</a></i> (<a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">Brentuximab</a>), <i><a href="/wiki/CD52" title="CD52">CD52</a></i> (<a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul> <ul><li><a href="/wiki/Myeloid" class="mw-redirect" title="Myeloid">myeloid</a>: <i><a href="/wiki/CD33" title="CD33">CD33</a></i> (<a href="/wiki/Gemtuzumab_ozogamicin" title="Gemtuzumab ozogamicin">Gemtuzumab ozogamicin</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Amivantamab" title="Amivantamab">Amivantamab</a></li> <li><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a> (<a href="/wiki/Atezolizumab/hyaluronidase" title="Atezolizumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li> <li><a href="/wiki/Axatilimab" title="Axatilimab">Axatilimab</a></li> <li><a href="/wiki/Belantamab_mafodotin" title="Belantamab mafodotin">Belantamab mafodotin</a></li> <li><a href="/wiki/Bermekimab" title="Bermekimab">Bermekimab</a></li> <li><a href="/wiki/Blinatumomab" title="Blinatumomab">Blinatumomab</a></li> <li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li> <li><a href="/wiki/Cosibelimab" title="Cosibelimab">Cosibelimab</a></li> <li><a href="/wiki/Daratumumab" title="Daratumumab">Daratumumab</a></li> <li><a href="/wiki/Dinutuximab_beta" class="mw-redirect" title="Dinutuximab beta">Dinutuximab beta</a></li> <li><a href="/wiki/Dostarlimab" title="Dostarlimab">Dostarlimab</a></li> <li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li> <li><a href="/wiki/Elotuzumab" title="Elotuzumab">Elotuzumab</a></li> <li><a href="/wiki/Enfortumab_vedotin" title="Enfortumab vedotin">Enfortumab vedotin</a></li> <li><a href="/wiki/Epcoritamab" title="Epcoritamab">Epcoritamab</a></li> <li><a href="/wiki/Inotuzumab_ozogamicin" title="Inotuzumab ozogamicin">Inotuzumab ozogamicin</a></li> <li><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li> <li><a href="/wiki/Isatuximab" title="Isatuximab">Isatuximab</a></li> <li><a href="/wiki/Linvoseltamab" title="Linvoseltamab">Linvoseltamab</a></li> <li><a href="/wiki/Loncastuximab_tesirine" title="Loncastuximab tesirine">Loncastuximab tesirine</a></li> <li><a href="/wiki/Mirvetuximab_soravtansine" title="Mirvetuximab soravtansine">Mirvetuximab soravtansine</a></li> <li><a href="/wiki/Mogamulizumab" title="Mogamulizumab">Mogamulizumab</a></li> <li><a href="/wiki/Moxetumomab_pasudotox" title="Moxetumomab pasudotox">Moxetumomab pasudotox</a></li> <li><a href="/wiki/Naxitamab" title="Naxitamab">Naxitamab</a></li> <li><a href="/wiki/Necitumumab" title="Necitumumab">Necitumumab</a></li> <li><a class="mw-selflink selflink">Nivolumab</a> (<a href="/wiki/Nivolumab/hyaluronidase" title="Nivolumab/hyaluronidase">+hyaluronidase</a>, <a href="/wiki/Nivolumab/relatlimab" title="Nivolumab/relatlimab">+relatlimab</a>)</li> <li><a href="/wiki/Olaratumab" title="Olaratumab">Olaratumab</a></li> <li><a href="/wiki/Oportuzumab_monatox" title="Oportuzumab monatox">Oportuzumab monatox</a></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li> <li><a href="/wiki/Polatuzumab_vedotin" title="Polatuzumab vedotin">Polatuzumab vedotin</a></li> <li><a href="/w/index.php?title=Prolgolimab&action=edit&redlink=1" class="new" title="Prolgolimab (page does not exist)">Prolgolimab</a></li> <li><a href="/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li> <li><a href="/wiki/Retifanlimab" title="Retifanlimab">Retifanlimab</a></li> <li><a href="/w/index.php?title=Sabatolimab&action=edit&redlink=1" class="new" title="Sabatolimab (page does not exist)">Sabatolimab</a></li> <li><a href="/wiki/Sacituzumab_govitecan" title="Sacituzumab govitecan">Sacituzumab govitecan</a></li> <li><a href="/wiki/Serplulimab" title="Serplulimab">Serplulimab</a></li> <li><a href="/wiki/Sugemalimab" title="Sugemalimab">Sugemalimab</a></li> <li><a href="/wiki/Tafasitamab" title="Tafasitamab">Tafasitamab</a></li> <li><a href="/wiki/Talquetamab" title="Talquetamab">Talquetamab</a></li> <li><a href="/wiki/Tarlatamab" title="Tarlatamab">Tarlatamab</a></li> <li><a href="/wiki/Teclistamab" title="Teclistamab">Teclistamab</a></li> <li><a href="/wiki/Tislelizumab" title="Tislelizumab">Tislelizumab</a></li> <li><a href="/wiki/Tisotumab_vedotin" title="Tisotumab vedotin">Tisotumab vedotin</a></li> <li><a href="/wiki/Toripalimab" title="Toripalimab">Toripalimab</a></li> <li><a href="/wiki/Tremelimumab" title="Tremelimumab">Tremelimumab</a></li> <li><a href="/wiki/Zenocutuzumab" title="Zenocutuzumab">Zenocutuzumab</a></li> <li><a href="/wiki/Zolbetuximab" title="Zolbetuximab">Zolbetuximab</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Tyrosine_kinase_inhibitor" title="Tyrosine kinase inhibitor">Tyrosine kinase inhibitors</a> ("-nib")</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">Receptor tyrosine kinase</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/ErbB" title="ErbB">ErbB</a>: <i><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">HER1/EGFR</a></i> (<a href="/wiki/Afatinib" title="Afatinib">Afatinib</a></li> <li><a href="/wiki/Aumolertinib" title="Aumolertinib">Aumolertinib</a></li> <li><a href="/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li> <li><a href="/wiki/Dacomitinib" title="Dacomitinib">Dacomitinib</a></li> <li><a href="/wiki/Erlotinib" title="Erlotinib">Erlotinib</a></li> <li><a href="/wiki/Gefitinib" title="Gefitinib">Gefitinib</a></li> <li><a href="/wiki/Icotinib" title="Icotinib">Icotinib</a></li> <li><a href="/wiki/Lazertinib" title="Lazertinib">Lazertinib</a></li> <li><a href="/wiki/Mobocertinib" title="Mobocertinib">Mobocertinib</a></li> <li><a href="/wiki/Olmutinib" title="Olmutinib">Olmutinib</a></li> <li><a href="/wiki/Osimertinib" title="Osimertinib">Osimertinib</a></li> <li><a href="/wiki/Rociletinib" title="Rociletinib">Rociletinib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a>)</li></ul> <ul><li><i>HER1/EGFR and <a href="/wiki/HER2/neu" class="mw-redirect" title="HER2/neu">HER2/neu</a></i> <ul><li><a href="/wiki/Lapatinib" title="Lapatinib">Lapatinib</a></li> <li><a href="/wiki/Neratinib" title="Neratinib">Neratinib</a></li> <li><a href="/wiki/Tucatinib" title="Tucatinib">Tucatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a></i> <ul><li><a href="/wiki/Dabrafenib" title="Dabrafenib">Dabrafenib</a></li> <li><a href="/wiki/Encorafenib" title="Encorafenib">Encorafenib</a></li> <li><a href="/wiki/Tovorafenib" title="Tovorafenib">Tovorafenib</a></li> <li><a href="/wiki/Vemurafenib" title="Vemurafenib">Vemurafenib</a></li></ul></li></ul> <ul><li><a href="/wiki/RTK_class_III" title="RTK class III">RTK class III</a>: <i><a href="/wiki/CD117" class="mw-redirect" title="CD117">C-kit</a> and <a href="/wiki/Platelet-derived_growth_factor_receptor" title="Platelet-derived growth factor receptor">PDGFR</a></i> (<a href="/wiki/Avapritinib" title="Avapritinib">Avapritinib</a></li> <li><a href="/wiki/Axitinib" title="Axitinib">Axitinib</a></li> <li><a href="/wiki/Masitinib" title="Masitinib">Masitinib</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a>)</li> <li><i><a href="/wiki/CD135" title="CD135">FLT3</a></i> (<a href="/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a>, <a href="/wiki/Gilteritinib" title="Gilteritinib">Gilteritinib</a> (AXL, ALK, LTK))</li></ul> <ul><li><i><a href="/wiki/VEGF_receptors" class="mw-redirect" title="VEGF receptors">VEGFR</a></i> <ul><li><a href="/wiki/Axitinib" title="Axitinib">Axitinib</a></li> <li><a href="/wiki/Cediranib" title="Cediranib">Cediranib</a></li> <li><a href="/wiki/Fruquintinib" title="Fruquintinib">Fruquintinib</a></li> <li><a href="/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li> <li><a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li> <li><a href="/wiki/Semaxanib" title="Semaxanib">Semaxanib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Tivozanib" title="Tivozanib">Tivozanib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a></i> <ul><li><a href="/wiki/Alectinib" title="Alectinib">Alectinib</a></li> <li><a href="/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li> <li><a href="/wiki/Ceritinib" title="Ceritinib">Ceritinib</a></li> <li><a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li> <li><a href="/wiki/Ensartinib" title="Ensartinib">Ensartinib</a></li> <li><a href="/wiki/Lorlatinib" title="Lorlatinib">Lorlatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/RET_proto-oncogene" title="RET proto-oncogene">RET</a> inhibitors:</i> <a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a> (ALK, ROS1, NTRK), <a href="/wiki/Futibatinib" title="Futibatinib">Futibatinib</a> (FGFR2), <a href="/wiki/Infigratinib" title="Infigratinib">Infigratinib</a>, <a href="/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a> (NTRK), <a href="/wiki/Pemigatinib" title="Pemigatinib">Pemigatinib</a> (FGFR), <a href="/wiki/Pralsetinib" title="Pralsetinib">Pralsetinib</a>, <a href="/wiki/Repotrectinib" title="Repotrectinib">Repotrectinib</a> (ROS1, TRK, ALK), <a href="/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a> (VEGFR, FGFR), <a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a> (VEGFR, EGFR).</li></ul> <ul><li><i><a href="/wiki/C-Met" class="mw-redirect" title="C-Met">c-MET</a> inhibitors:</i> <a href="/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a> (VEGFR), <a href="/wiki/Capmatinib" title="Capmatinib">Capmatinib</a>, <a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a> (ALK)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Non-receptor_tyrosine_kinase" title="Non-receptor tyrosine kinase">Non-receptor</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Bcr-abl_fusion_protein" class="mw-redirect" title="Bcr-abl fusion protein">bcr-abl</a></i> <ul><li><a href="/wiki/Asciminib" title="Asciminib">Asciminib</a></li> <li><a href="/wiki/Bosutinib" title="Bosutinib">Bosutinib</a></li> <li><a href="/wiki/Dasatinib" title="Dasatinib">Dasatinib</a></li> <li><a href="/wiki/Imatinib" title="Imatinib">Imatinib</a></li> <li><a href="/wiki/Nilotinib" title="Nilotinib">Nilotinib</a></li> <li><a href="/wiki/Ponatinib" title="Ponatinib">Ponatinib</a></li> <li><a href="/wiki/Radotinib" title="Radotinib">Radotinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Src_(gene)" class="mw-redirect" title="Src (gene)">Src</a></i> (<a href="/wiki/Bosutinib" title="Bosutinib">Bosutinib</a></li> <li><a href="/wiki/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul> <ul><li><i><a href="/wiki/Janus_kinase" title="Janus kinase">Janus kinase</a> (JAK)</i> <ul><li><a href="/wiki/Baricitinib" title="Baricitinib">Baricitinib</a></li> <li><a href="/wiki/Fedratinib" title="Fedratinib">Fedratinib</a></li> <li><a href="/wiki/Filgotinib" title="Filgotinib">Filgotinib</a></li> <li><a href="/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a></li> <li><a href="/wiki/Momelotinib" title="Momelotinib">Momelotinib</a></li> <li><a href="/wiki/Pacritinib" title="Pacritinib">Pacritinib</a></li> <li><a href="/wiki/Ruxolitinib" title="Ruxolitinib">Ruxolitinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Mitogen-activated_protein_kinase_kinase" title="Mitogen-activated protein kinase kinase">MAP2K</a> (MEK)</i> <ul><li><a href="/wiki/Binimetinib" title="Binimetinib">Binimetinib</a></li> <li><a href="/wiki/Cobimetinib" title="Cobimetinib">Cobimetinib</a></li> <li><a href="/wiki/Mirdametinib" title="Mirdametinib">Mirdametinib</a></li> <li><a href="/wiki/Selumetinib" title="Selumetinib">Selumetinib</a></li> <li><a href="/wiki/Trametinib" title="Trametinib">Trametinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/EML4" title="EML4">EML4</a>-<a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a></i> <ul><li><a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li> <li><a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li> <li><a href="/wiki/Lorlatinib" title="Lorlatinib">Lorlatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Bruton%27s_tyrosine_kinase" title="Bruton's tyrosine kinase">Bruton's</a> (BTK)</i> <ul><li><a href="/wiki/Acalabrutinib" title="Acalabrutinib">Acalabrutinib</a></li> <li><a href="/wiki/Ibrutinib" title="Ibrutinib">Ibrutinib</a></li> <li><a href="/wiki/Orelabrutinib" title="Orelabrutinib">Orelabrutinib</a></li> <li><a href="/wiki/Pirtobrutinib" title="Pirtobrutinib">Pirtobrutinib</a></li> <li><a href="/wiki/Zanubrutinib" title="Zanubrutinib">Zanubrutinib</a></li></ul></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Fusion_protein" title="Fusion protein">fusion protein</a> against <a href="/wiki/Vascular_endothelial_growth_factor" title="Vascular endothelial growth factor">VEGF</a></i> (<a href="/wiki/Aflibercept" title="Aflibercept">Aflibercept</a>)</li></ul> <ul><li><i><a href="/wiki/Proapoptotic" class="mw-redirect" title="Proapoptotic">proapoptotic</a> peptide against <a href="/wiki/ANXA2" class="mw-redirect" title="ANXA2">ANXA2</a> and <a href="/wiki/Prohibitin" title="Prohibitin">prohibitin</a></i> (<a href="/wiki/Adipotide" class="mw-redirect" title="Adipotide">Adipotide</a>)</li></ul> <ul><li><i><a href="/wiki/Exotoxin" title="Exotoxin">exotoxin</a> against <a href="/wiki/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="/wiki/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li></ul> <ul><li><i><a href="/wiki/MTOR_inhibitor" class="mw-redirect" title="MTOR inhibitor">mTOR inhibitors</a></i> <ul><li><a href="/wiki/Everolimus" title="Everolimus">Everolimus</a></li> <li><a href="/wiki/Ridaforolimus" title="Ridaforolimus">Ridaforolimus</a></li> <li><a href="/wiki/Sirolimus" title="Sirolimus">Sirolimus</a></li> <li><a href="/wiki/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Hedgehog_signaling_pathway" title="Hedgehog signaling pathway">hedgehog</a> inhibitors</i> <ul><li><a href="/wiki/Glasdegib" title="Glasdegib">Glasdegib</a></li> <li><a href="/wiki/Sonidegib" title="Sonidegib">Sonidegib</a></li> <li><a href="/wiki/Vismodegib" title="Vismodegib">Vismodegib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/CDK_inhibitor" title="CDK inhibitor">CDK inhibitors</a></i> <ul><li><a href="/wiki/Abemaciclib" title="Abemaciclib">Abemaciclib</a></li> <li><a href="/wiki/Dalpiciclib" title="Dalpiciclib">Dalpiciclib</a></li> <li><a href="/wiki/Palbociclib" title="Palbociclib">Palbociclib</a></li> <li><a href="/wiki/Ribociclib" title="Ribociclib">Ribociclib</a></li> <li><a href="/wiki/Trilaciclib" title="Trilaciclib">Trilaciclib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/KRAS" title="KRAS">KRAS</a> inhibitors</i> <ul><li><a href="/wiki/Adagrasib" title="Adagrasib">Adagrasib</a></li> <li><a href="/wiki/Sotorasib" title="Sotorasib">Sotorasib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Pi3K_inhibitor" class="mw-redirect" title="Pi3K inhibitor">Pi3K inhibitors</a></i> <ul><li><a href="/wiki/Alpelisib" title="Alpelisib">Alpelisib</a></li> <li><a href="/wiki/Copanlisib" title="Copanlisib">Copanlisib</a></li> <li><a href="/wiki/Duvelisib" title="Duvelisib">Duvelisib</a></li> <li><a href="/wiki/Idelalisib" title="Idelalisib">Idelalisib</a></li> <li><a href="/wiki/Inavolisib" title="Inavolisib">Inavolisib</a></li> <li><a href="/wiki/Parsaclisib" title="Parsaclisib">Parsaclisib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/MEN1" title="MEN1">Menin</a> inhibitors</i> <ul><li><a href="/wiki/Revumenib" title="Revumenib">Revumenib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Fibroblast_growth_factor_receptor" title="Fibroblast growth factor receptor">Fibroblast growth factor receptor</a></i> (FGFR) inhibitors</li> <li><a href="/wiki/Erdafitinib" title="Erdafitinib">Erdafitinib</a></li> <li><a href="/wiki/Futibatinib" title="Futibatinib">Futibatinib</a></li> <li><a href="/wiki/Infigratinib" title="Infigratinib">Infigratinib</a></li> <li><a href="/wiki/Pemigatinib" title="Pemigatinib">Pemigatinib</a></li></ul> <ul><li><a href="/wiki/Avapritinib" title="Avapritinib">Avapritinib</a></li> <li><a href="/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a></li> <li><a href="/wiki/Capivasertib" title="Capivasertib">Capivasertib</a></li> <li><a href="/wiki/Capmatinib" title="Capmatinib">Capmatinib</a></li> <li><a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li> <li><a href="/wiki/Gilteritinib" title="Gilteritinib">Gilteritinib</a></li> <li><a href="/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a></li> <li><a href="/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li> <li><a href="/wiki/Masitinib" title="Masitinib">Masitinib</a></li> <li><a href="/wiki/Midostaurin" title="Midostaurin">Midostaurin</a></li> <li><a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li> <li><a href="/wiki/Odronextamab" title="Odronextamab">Odronextamab</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Pexidartinib" title="Pexidartinib">Pexidartinib</a></li> <li><a href="/wiki/Pralsetinib" title="Pralsetinib">Pralsetinib</a></li> <li><a href="/wiki/Quizartinib" title="Quizartinib">Quizartinib</a></li> <li><a href="/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li> <li><a href="/wiki/Repotrectinib" title="Repotrectinib">Repotrectinib</a></li> <li><a href="/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li> <li><a href="/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a></li> <li><a href="/wiki/Sitravatinib" title="Sitravatinib">Sitravatinib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Surufatinib" title="Surufatinib">Surufatinib</a></li> <li><a href="/wiki/Tebentafusp" title="Tebentafusp">Tebentafusp</a></li> <li><a href="/wiki/Tepotinib" title="Tepotinib">Tepotinib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a></li> <li><a href="/wiki/Tunlametinib" title="Tunlametinib">Tunlametinib</a></li> <li><a href="/wiki/Umbralisib" title="Umbralisib">Umbralisib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li> <li><a href="/wiki/Venetoclax" title="Venetoclax">Venetoclax</a></li> <li><a href="/wiki/Vimseltinib" title="Vimseltinib">Vimseltinib</a></li></ul> </div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235" /></div><div role="navigation" class="navbox" aria-labelledby="PD-1_and_PD-L1_inhibitors874" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231" /><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:PD-1_and_PD-L1_inhibitors" title="Template:PD-1 and PD-L1 inhibitors"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/w/index.php?title=Template_talk:PD-1_and_PD-L1_inhibitors&action=edit&redlink=1" class="new" title="Template talk:PD-1 and PD-L1 inhibitors (page does not exist)"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:PD-1_and_PD-L1_inhibitors" title="Special:EditPage/Template:PD-1 and PD-L1 inhibitors"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="PD-1_and_PD-L1_inhibitors874" style="font-size:114%;margin:0 4em"><a href="/wiki/PD-1_and_PD-L1_inhibitors" title="PD-1 and PD-L1 inhibitors">PD-1 and PD-L1 inhibitors</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Programmed_cell_death_protein_1" title="Programmed cell death protein 1"><abbr title="Programmed cell death protein 1">PD-1 inhibitors</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Programmed cell death protein 1</span></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a class="mw-selflink selflink">Nivolumab</a></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li> <li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li> <li><a href="/wiki/Dostarlimab" title="Dostarlimab">Dostarlimab</a></li> <li><a href="/wiki/Retifanlimab" title="Retifanlimab">Retifanlimab</a></li> <li><a href="/wiki/Toripalimab" title="Toripalimab">Toripalimab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Programmed_death-ligand_1" class="mw-redirect" title="Programmed death-ligand 1"><abbr title="Programmed death-ligand 1">PD-L1 inhibitors</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Programmed death-ligand 1</span></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/BMS-202" title="BMS-202">BMS-202</a></li> <li><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a></li> <li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li> <li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li> <li><a href="/w/index.php?title=KN035&action=edit&redlink=1" class="new" title="KN035 (page does not exist)">KN035</a></li> <li><a href="/wiki/Cosibelimab" title="Cosibelimab">Cosibelimab</a></li> <li><a href="/w/index.php?title=AUNP12&action=edit&redlink=1" class="new" title="AUNP12 (page does not exist)">AUNP12</a></li> <li><a href="/w/index.php?title=CA-170&action=edit&redlink=1" class="new" title="CA-170 (page does not exist)">CA-170</a></li> <li><a href="/w/index.php?title=BMS-986189&action=edit&redlink=1" class="new" title="BMS-986189 (page does not exist)">BMS-986189</a></li></ul> </div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /></div><div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors398" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231" /><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Monoclonals_for_tumors" title="Template:Monoclonals for tumors"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Monoclonals_for_tumors" title="Template talk:Monoclonals for tumors"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Monoclonals_for_tumors" title="Special:EditPage/Template:Monoclonals for tumors"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Monoclonal_antibodies_for_tumors398" style="font-size:114%;margin:0 4em"><a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">Monoclonal antibodies</a> for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;"><a href="/wiki/Neoplasm" title="Neoplasm">Tumor</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Adecatumumab" title="Adecatumumab">Adecatumumab</a><sup>§</sup></li> <li><a href="/wiki/Amivantamab" title="Amivantamab">Amivantamab</a></li> <li><a href="/wiki/Ascrinvacumab" title="Ascrinvacumab">Ascrinvacumab</a><sup>§</sup></li> <li><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a> (<a href="/wiki/Atezolizumab/hyaluronidase" title="Atezolizumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/w/index.php?title=Balstilimab&action=edit&redlink=1" class="new" title="Balstilimab (page does not exist)">Balstilimab</a><sup>†</sup></li> <li><a href="/w/index.php?title=Botensilimab&action=edit&redlink=1" class="new" title="Botensilimab (page does not exist)">Botensilimab</a></li> <li><a href="/wiki/Cixutumumab" title="Cixutumumab">Cixutumumab</a><sup>§</sup></li> <li><a href="/wiki/Conatumumab" title="Conatumumab">Conatumumab</a><sup>§</sup></li> <li><a href="/wiki/Cosibelimab" title="Cosibelimab">Cosibelimab</a></li> <li><a href="/wiki/Daratumumab" title="Daratumumab">Daratumumab</a></li> <li><a href="/wiki/Drozitumab" title="Drozitumab">Drozitumab</a><sup>§</sup></li> <li><a href="/wiki/Duligotumab" class="mw-redirect" title="Duligotumab">Duligotumab</a><sup>§</sup></li> <li><a href="/wiki/Dusigitumab" title="Dusigitumab">Dusigitumab</a><sup>§</sup></li> <li><a href="/wiki/Enfortumab_vedotin" title="Enfortumab vedotin">Enfortumab vedotin</a></li> <li><a href="/wiki/Enoticumab" title="Enoticumab">Enoticumab</a><sup>§</sup></li> <li><a href="/wiki/Figitumumab" title="Figitumumab">Figitumumab</a><sup>§</sup></li> <li><a href="/wiki/Flanvotumab" title="Flanvotumab">Flanvotumab</a><sup>§</sup></li> <li><a href="/wiki/Ganitumab" title="Ganitumab">Ganitumab</a><sup>†</sup></li> <li><a href="/wiki/Glembatumumab_vedotin" title="Glembatumumab vedotin">Glembatumumab vedotin</a><sup>†</sup></li> <li><a href="/wiki/Intetumumab" title="Intetumumab">Intetumumab</a><sup>§</sup></li> <li><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li> <li><a href="/wiki/Iratumumab" title="Iratumumab">Iratumumab</a><sup>§</sup></li> <li><a href="/wiki/Istiratumab" title="Istiratumab">Istiratumab</a></li> <li><a href="/wiki/Icrucumab" title="Icrucumab">Icrucumab</a><sup>§</sup></li> <li><a href="/wiki/Lexatumumab" title="Lexatumumab">Lexatumumab</a><sup>§</sup></li> <li><a href="/wiki/Linvoseltamab" title="Linvoseltamab">Linvoseltamab</a></li> <li><a href="/wiki/Lucatumumab" title="Lucatumumab">Lucatumumab</a><sup>§</sup></li> <li><a href="/wiki/Mapatumumab" title="Mapatumumab">Mapatumumab</a><sup>§</sup></li> <li><a href="/wiki/Narnatumab" title="Narnatumab">Narnatumab</a><sup>§</sup></li> <li><a href="/wiki/Necitumumab" title="Necitumumab">Necitumumab</a></li> <li><a href="/wiki/Nesvacumab" title="Nesvacumab">Nesvacumab</a><sup>§</sup></li> <li><a class="mw-selflink selflink">Nivolumab</a><sup>#</sup> (<a href="/wiki/Nivolumab/hyaluronidase" title="Nivolumab/hyaluronidase">+hyaluronidase</a>, <a href="/wiki/Nivolumab/relatlimab" title="Nivolumab/relatlimab">+relatlimab</a>)</li> <li><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a></li> <li><a href="/wiki/Olaratumab" title="Olaratumab">Olaratumab</a><sup>†</sup></li> <li><a href="/wiki/Panitumumab" title="Panitumumab">Panitumumab</a></li> <li><a href="/wiki/Patritumab" title="Patritumab">Patritumab</a><sup>§</sup></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a><sup>#</sup></li> <li><a href="/wiki/Pritumumab" title="Pritumumab">Pritumumab</a><sup>§</sup></li> <li><a href="/wiki/Radretumab" title="Radretumab">Radretumab</a><sup>§</sup></li> <li><a href="/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li> <li><a href="/wiki/Rilotumumab" title="Rilotumumab">Rilotumumab</a><sup>†</sup></li> <li><a href="/wiki/Robatumumab" title="Robatumumab">Robatumumab</a><sup>§</sup></li> <li><a href="/wiki/Seribantumab" title="Seribantumab">Seribantumab</a><sup>§</sup></li> <li><a href="/wiki/Sugemalimab" title="Sugemalimab">Sugemalimab</a></li> <li><a href="/wiki/Tarextumab" title="Tarextumab">Tarextumab</a><sup>§</sup></li> <li><a href="/wiki/Tisotumab_vedotin" title="Tisotumab vedotin">Tisotumab vedotin</a></li> <li><a href="/wiki/Teprotumumab" title="Teprotumumab">Teprotumumab</a><sup>†</sup></li> <li><a href="/wiki/Tovetumab" title="Tovetumab">Tovetumab</a><sup>§</sup></li> <li><a href="/wiki/Vantictumab" title="Vantictumab">Vantictumab</a><sup>§</sup></li> <li><a href="/wiki/Technetium_(99mTc)_votumumab" title="Technetium (99mTc) votumumab">Votumumab</a><sup>§</sup></li> <li><a href="/wiki/Zalutumumab" title="Zalutumumab">Zalutumumab</a><sup>†</sup></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Abagovomab" title="Abagovomab">Abagovomab</a></li> <li><a href="/wiki/Indium_(111In)_altumomab_pentetate" title="Indium (111In) altumomab pentetate">Altumomab pentetate</a></li> <li><a href="/wiki/Anatumomab_mafenatox" title="Anatumomab mafenatox">Anatumomab mafenatox</a></li> <li><a href="/wiki/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li> <li><a href="/wiki/Bectumomab" title="Bectumomab">Bectumomab</a></li> <li><a href="/wiki/Blinatumomab" title="Blinatumomab">Blinatumomab</a></li> <li><a href="/wiki/Indium_(111In)_capromab_pendetide" title="Indium (111In) capromab pendetide">Capromab pendetide</a></li> <li><a href="/wiki/Detumomab" title="Detumomab">Detumomab</a></li> <li><a href="/wiki/Edrecolomab" title="Edrecolomab">Edrecolomab</a></li> <li><a href="/wiki/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li> <li><a href="/wiki/Indium_(111In)_igovomab" title="Indium (111In) igovomab">Igovomab</a></li> <li><a href="/wiki/Lilotomab" title="Lilotomab">Lilotomab</a></li> <li><a href="/wiki/Minretumomab" title="Minretumomab">Minretumomab</a></li> <li><a href="/wiki/Mitumomab" title="Mitumomab">Mitumomab</a></li> <li><a href="/wiki/Nacolomab_tafenatox" title="Nacolomab tafenatox">Nacolomab tafenatox</a></li> <li><a href="/wiki/Moxetumomab_pasudotox" title="Moxetumomab pasudotox">Moxetumomab pasudotox</a></li> <li><a href="/wiki/Naptumomab_estafenatox" title="Naptumomab estafenatox">Naptumomab estafenatox</a></li> <li><a href="/wiki/Oregovomab" title="Oregovomab">Oregovomab</a></li> <li><a href="/wiki/Pemtumomab" title="Pemtumomab">Pemtumomab</a><sup>†</sup></li> <li><a href="/wiki/Racotumomab" title="Racotumomab">Racotumomab</a></li> <li><a href="/wiki/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li> <li><a href="/wiki/Solitomab" title="Solitomab">Solitomab</a></li> <li><a href="/wiki/Taplitumomab_paptox" title="Taplitumomab paptox">Taplitumomab paptox</a></li> <li><a href="/wiki/Technetium_(99mTc)_nofetumomab_merpentan" title="Technetium (99mTc) nofetumomab merpentan">Nofetumomab merpentan</a></li> <li><a href="/wiki/Technetium_(99mTc)_pintumomab" title="Technetium (99mTc) pintumomab">Pintumomab</a></li> <li><a href="/wiki/Tenatumomab" title="Tenatumomab">Tenatumomab</a></li> <li><a href="/wiki/Tositumomab" title="Tositumomab">Tositumomab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Chimeric_antibody" class="mw-redirect" title="Chimeric antibody">Chimeric</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Amatuximab" title="Amatuximab">Amatuximab</a><sup>§</sup></li> <li><a href="/wiki/Bavituximab" title="Bavituximab">Bavituximab</a><sup>§</sup></li> <li><a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">Brentuximab vedotin</a></li> <li><a href="/wiki/Carotuximab" title="Carotuximab">Carotuximab</a><sup>†</sup></li> <li><a href="/wiki/Cetuximab" title="Cetuximab">Cetuximab</a></li> <li><a href="/wiki/Iodine_(131_I)_derlotuximab_biotin" title="Iodine (131 I) derlotuximab biotin">Derlotuximab biotin</a><sup>§</sup></li> <li><a href="/wiki/Dinutuximab" title="Dinutuximab">Dinutuximab</a></li> <li><a href="/wiki/Ecromeximab" title="Ecromeximab">Ecromeximab</a><sup>§</sup></li> <li><a href="/wiki/Ensituximab" title="Ensituximab">Ensituximab</a><sup>§</sup></li> <li><a href="/wiki/Futuximab" title="Futuximab">Futuximab</a><sup>§</sup></li> <li><a href="/wiki/Girentuximab" title="Girentuximab">Girentuximab</a><sup>†</sup></li> <li><a href="/wiki/Indatuximab_ravtansine" title="Indatuximab ravtansine">Indatuximab ravtansine</a><sup>§</sup></li> <li><a href="/wiki/Isatuximab" title="Isatuximab">Isatuximab</a></li> <li><a href="/wiki/Loncastuximab_tesirine" title="Loncastuximab tesirine">Loncastuximab tesirine</a></li> <li><a href="/wiki/Margetuximab" title="Margetuximab">Margetuximab</a></li> <li><a href="/wiki/Mirvetuximab_soravtansine" title="Mirvetuximab soravtansine">Mirvetuximab soravtansine</a></li> <li><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li> <li><a href="/wiki/Siltuximab" title="Siltuximab">Siltuximab</a></li> <li><a href="/wiki/Ublituximab" title="Ublituximab">Ublituximab</a></li> <li><a href="/wiki/Zolbetuximab" title="Zolbetuximab">Zolbetuximab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Humanized_antibody" title="Humanized antibody">Humanized</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Abituzumab" title="Abituzumab">Abituzumab</a><sup>§</sup></li> <li><a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li> <li><a href="/wiki/Axatilimab" title="Axatilimab">Axatilimab</a></li> <li><a href="/wiki/Belantamab_mafodotin" title="Belantamab mafodotin">Belantamab mafodotin</a></li> <li><a href="/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a></li> <li><a href="/wiki/Bivatuzumab_mertansine" title="Bivatuzumab mertansine">Bivatuzumab mertansine</a><sup>§</sup></li> <li><a href="/wiki/Brontictuzumab" title="Brontictuzumab">Brontictuzumab</a><sup>§</sup></li> <li><a href="/wiki/Cantuzumab_mertansine" title="Cantuzumab mertansine">Cantuzumab mertansine</a><sup>§</sup></li> <li><a href="/wiki/Cantuzumab_ravtansine" title="Cantuzumab ravtansine">Cantuzumab ravtansine</a><sup>§</sup></li> <li><a href="/wiki/Cirmtuzumab" title="Cirmtuzumab">Cirmtuzumab</a></li> <li><a href="/wiki/Citatuzumab_bogatox" title="Citatuzumab bogatox">Citatuzumab bogatox</a><sup>§</sup></li> <li><a href="/wiki/Yttrium_(90Y)_clivatuzumab_tetraxetan" title="Yttrium (90Y) clivatuzumab tetraxetan">Clivatuzumab tetraxetan</a></li> <li><a href="/wiki/Cofetuzumab_pelidotin" title="Cofetuzumab pelidotin">Cofetuzumab pelidotin</a></li> <li><a href="/wiki/Dacetuzumab" title="Dacetuzumab">Dacetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Demcizumab" title="Demcizumab">Demcizumab</a><sup>§</sup></li> <li><a href="/wiki/Dalotuzumab" title="Dalotuzumab">Dalotuzumab</a><sup>§</sup></li> <li><a href="/wiki/Datopotamab_deruxtecan" title="Datopotamab deruxtecan">Datopotamab deruxtecan</a></li> <li><a href="/wiki/Denintuzumab_mafodotin" title="Denintuzumab mafodotin">Denintuzumab mafodotin</a><sup>§</sup></li> <li><a href="/wiki/Elotuzumab" title="Elotuzumab">Elotuzumab</a></li> <li><a href="/wiki/Emactuzumab" title="Emactuzumab">Emactuzumab</a></li> <li><a href="/wiki/Emibetuzumab" title="Emibetuzumab">Emibetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Enoblituzumab" title="Enoblituzumab">Enoblituzumab</a><sup>§</sup></li> <li><a href="/wiki/Epcoritamab" title="Epcoritamab">Epcoritamab</a></li> <li><a href="/wiki/Etaracizumab" title="Etaracizumab">Etaracizumab</a><sup>§</sup></li> <li><a href="/wiki/Farletuzumab" title="Farletuzumab">Farletuzumab</a><sup>§</sup></li> <li><a href="/wiki/Ficlatuzumab" title="Ficlatuzumab">Ficlatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Flotetuzumab" title="Flotetuzumab">Flotetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Gemtuzumab_ozogamicin" title="Gemtuzumab ozogamicin">Gemtuzumab ozogamicin</a></li> <li><a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a></li> <li><a href="/wiki/Imgatuzumab" title="Imgatuzumab">Imgatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Inotuzumab_ozogamicin" title="Inotuzumab ozogamicin">Inotuzumab ozogamicin</a></li> <li><a href="/wiki/Labetuzumab" title="Labetuzumab">Labetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Lifastuzumab_vedotin" title="Lifastuzumab vedotin">Lifastuzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Lintuzumab" title="Lintuzumab">Lintuzumab</a><sup>§</sup></li> <li><a href="/wiki/Lorvotuzumab_mertansine" title="Lorvotuzumab mertansine">Lorvotuzumab mertansine</a><sup>§</sup></li> <li><a href="/wiki/Lumretuzumab" title="Lumretuzumab">Lumretuzumab</a><sup>§</sup></li> <li><a href="/wiki/Matuzumab" title="Matuzumab">Matuzumab</a><sup>§</sup></li> <li><a href="/wiki/Milatuzumab" title="Milatuzumab">Milatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Naxitamab" title="Naxitamab">Naxitamab</a></li> <li><a href="/wiki/Nimotuzumab" title="Nimotuzumab">Nimotuzumab</a><sup>†</sup></li> <li><a href="/wiki/Obinutuzumab" title="Obinutuzumab">Obinutuzumab</a></li> <li><a href="/wiki/Ocaratuzumab" title="Ocaratuzumab">Ocaratuzumab</a><sup>§</sup></li> <li><a href="/wiki/Odronextamab" title="Odronextamab">Odronextamab</a></li> <li><a href="/wiki/Otlertuzumab" title="Otlertuzumab">Otlertuzumab</a><sup>§</sup></li> <li><a href="/wiki/Onartuzumab" title="Onartuzumab">Onartuzumab</a><sup>§</sup></li> <li><a href="/wiki/Oportuzumab_monatox" title="Oportuzumab monatox">Oportuzumab monatox</a><sup>†</sup></li> <li><a href="/wiki/Parsatuzumab" title="Parsatuzumab">Parsatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Pertuzumab" title="Pertuzumab">Pertuzumab</a></li> <li><a href="/wiki/Pinatuzumab_vedotin" title="Pinatuzumab vedotin">Pinatuzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Polatuzumab_vedotin" title="Polatuzumab vedotin">Polatuzumab vedotin</a></li> <li><a href="/wiki/Rosmantuzumab" title="Rosmantuzumab">Rosmantuzumab</a></li> <li><a href="/wiki/Rovalpituzumab_tesirine" title="Rovalpituzumab tesirine">Rovalpituzumab tesirine</a><sup>†</sup></li> <li><a href="/wiki/Sacituzumab_govitecan" title="Sacituzumab govitecan">Sacituzumab govitecan</a></li> <li><a href="/wiki/Sibrotuzumab" title="Sibrotuzumab">Sibrotuzumab</a><sup>§</sup></li> <li><a href="/wiki/Simtuzumab" title="Simtuzumab">Simtuzumab</a><sup>§</sup></li> <li><a href="/wiki/Sofituzumab_vedotin" title="Sofituzumab vedotin">Sofituzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Yttrium_(90Y)_tacatuzumab_tetraxetan" title="Yttrium (90Y) tacatuzumab tetraxetan">Tacatuzumab tetraxetan</a><sup>§</sup></li> <li><a href="/wiki/Tigatuzumab" title="Tigatuzumab">Tigatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup> (<a href="/wiki/Trastuzumab_deruxtecan" title="Trastuzumab deruxtecan">+deruxtecan</a> / <a href="/wiki/Trastuzumab_emtansine" title="Trastuzumab emtansine">+emtansine</a>)</li> <li><a href="/wiki/Tucotuzumab_celmoleukin" title="Tucotuzumab celmoleukin">Tucotuzumab celmoleukin</a><sup>§</sup></li> <li><a href="/wiki/Vandortuzumab_vedotin" title="Vandortuzumab vedotin">Vandortuzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Vanucizumab" title="Vanucizumab">Vanucizumab</a><sup>§</sup></li> <li><a href="/wiki/Veltuzumab" title="Veltuzumab">Veltuzumab</a><sup>§</sup></li> <li><a href="/wiki/Vorsetuzumab_mafodotin" title="Vorsetuzumab mafodotin">Vorsetuzumab mafodotin</a><sup>§</sup></li> <li><a href="/wiki/Zenocutuzumab" title="Zenocutuzumab">Zenocutuzumab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Trifunctional_antibody" title="Trifunctional antibody">Rat/mouse hybrid</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Catumaxomab" title="Catumaxomab">Catumaxomab</a></li> <li><a href="/wiki/Ertumaxomab" title="Ertumaxomab">Ertumaxomab</a><sup>§</sup></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Depatuxizumab_mafodotin" title="Depatuxizumab mafodotin">Depatuxizumab mafodotin</a><sup>†</sup></li> <li><a href="/wiki/Duvortuxizumab" title="Duvortuxizumab">Duvortuxizumab</a></li> <li><a href="/wiki/Ontuxizumab" title="Ontuxizumab">Ontuxizumab</a><sup>§</sup></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="padding: 0px;"><div><div class="hlist"> <ul><li><sup>#</sup><a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li> <li><sup>‡</sup><a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li> <li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>: <ul><li><sup>†</sup><a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li> <li><sup>§</sup>Never to phase III</li></ul></li></ul> </div></div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /></div><div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_the_immune_system431" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374" /><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231" /><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Monoclonals_for_immune_system" title="Template:Monoclonals for immune system"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Monoclonals_for_immune_system" title="Template talk:Monoclonals for immune system"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Monoclonals_for_immune_system" title="Special:EditPage/Template:Monoclonals for immune system"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Monoclonal_antibodies_for_the_immune_system431" style="font-size:114%;margin:0 4em"><a href="/wiki/Monoclonal_antibodies" class="mw-redirect" title="Monoclonal antibodies">Monoclonal antibodies</a> for the <a href="/wiki/Immune_system" title="Immune system">immune system</a></div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%"><a href="/wiki/Immune_system" title="Immune system">Immune system</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Immunosuppression" title="Immunosuppression">Immunosuppression</a></i>: <a href="/wiki/Abrilumab" title="Abrilumab">Abrilumab</a></li> <li><a href="/wiki/Adalimumab" title="Adalimumab">Adalimumab</a><sup>#</sup></li> <li><a href="/wiki/Anifrolumab" title="Anifrolumab">Anifrolumab</a></li> <li><a href="/wiki/Atorolimumab" title="Atorolimumab">Atorolimumab</a></li> <li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li> <li><a href="/w/index.php?title=Avdoralimab&action=edit&redlink=1" class="new" title="Avdoralimab (page does not exist)">Avdoralimab</a></li> <li><a href="/wiki/Belimumab" title="Belimumab">Belimumab</a></li> <li><a href="/wiki/Bleselumab" title="Bleselumab">Bleselumab</a></li> <li><a href="/wiki/Brodalumab" title="Brodalumab">Brodalumab</a></li> <li><a href="/wiki/Camidanlumab_tesirine" title="Camidanlumab tesirine">Camidanlumab tesirine</a></li> <li><a href="/wiki/Carlumab" title="Carlumab">Carlumab</a></li> <li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li> <li><a href="/wiki/Dupilumab" title="Dupilumab">Dupilumab</a></li> <li><a href="/wiki/Eldelumab" title="Eldelumab">Eldelumab</a></li> <li><a href="/wiki/Emapalumab" title="Emapalumab">Emapalumab</a></li> <li><a href="/wiki/Fresolimumab" title="Fresolimumab">Fresolimumab</a></li> <li><a href="/wiki/Golimumab" title="Golimumab">Golimumab</a></li> <li><a href="/wiki/Ianalumab" title="Ianalumab">Ianalumab</a><sup>†</sup></li> <li><a href="/wiki/Lanadelumab" title="Lanadelumab">Lanadelumab</a></li> <li><a href="/wiki/Lenzilumab" title="Lenzilumab">Lenzilumab</a></li> <li><a href="/wiki/Lerdelimumab" title="Lerdelimumab">Lerdelimumab</a></li> <li><a href="/wiki/Lirentelimab" title="Lirentelimab">Lirentelimab</a></li> <li><a href="/wiki/Lirilumab" title="Lirilumab">Lirilumab</a></li> <li><a href="/wiki/Mavrilimumab" title="Mavrilimumab">Mavrilimumab</a></li> <li><a href="/wiki/Metelimumab" title="Metelimumab">Metelimumab</a></li> <li><a href="/wiki/Morolimumab" title="Morolimumab">Morolimumab</a></li> <li><a href="/wiki/Namilumab" title="Namilumab">Namilumab</a></li> <li><a href="/wiki/Oleclumab" title="Oleclumab">Oleclumab</a></li> <li><a href="/wiki/Oxelumab" title="Oxelumab">Oxelumab</a>§</li> <li><a href="/wiki/Pamrevlumab" title="Pamrevlumab">Pamrevlumab</a></li> <li><a href="/wiki/Placulumab" title="Placulumab">Placulumab</a></li> <li><a href="/wiki/Relatlimab" title="Relatlimab">Relatlimab</a><sup>†</sup></li> <li><a href="/wiki/Sarilumab" title="Sarilumab">Sarilumab</a></li> <li><a href="/wiki/Sifalimumab" title="Sifalimumab">Sifalimumab</a></li> <li><a href="/wiki/Tabalumab" title="Tabalumab">Tabalumab</a></li> <li><a href="/wiki/Tezepelumab" title="Tezepelumab">Tezepelumab</a></li> <li><a href="/wiki/Ulocuplumab" title="Ulocuplumab">Ulocuplumab</a></li> <li><a href="/wiki/Varlilumab" title="Varlilumab">Varlilumab</a></li></ul> <ul><li><i>Immune activation</i>: <a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li> <li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li> <li><a class="mw-selflink selflink">Nivolumab</a></li> <li><a href="/wiki/Tremelimumab" title="Tremelimumab">Tremelimumab</a></li> <li><a href="/wiki/Urelumab" title="Urelumab">Urelumab</a></li></ul> <ul><li><i>Other</i>: <a href="/wiki/Bertilimumab" title="Bertilimumab">Bertilimumab</a></li> <li><a href="/w/index.php?title=Ontamalimab&action=edit&redlink=1" class="new" title="Ontamalimab (page does not exist)">Ontamalimab</a></li> <li><a href="/wiki/Zanolimumab" title="Zanolimumab">Zanolimumab</a></li></ul> <ul><li><i>Combination</i>: <a href="/wiki/Nivolumab/relatlimab" title="Nivolumab/relatlimab">Nivolumab/relatlimab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Afelimomab" title="Afelimomab">Afelimomab</a></li> <li><a href="/wiki/Elsilimomab" title="Elsilimomab">Elsilimomab</a></li> <li><a href="/wiki/Faralimomab" title="Faralimomab">Faralimomab</a></li> <li><a href="/wiki/Gavilimomab" title="Gavilimomab">Gavilimomab</a></li> <li><a href="/wiki/Inolimomab" title="Inolimomab">Inolimomab</a></li> <li><a href="/wiki/Maslimomab" title="Maslimomab">Maslimomab</a></li> <li><a href="/wiki/Nerelimomab" title="Nerelimomab">Nerelimomab</a></li> <li><a href="/wiki/Odulimomab" title="Odulimomab">Odulimomab</a></li> <li><a href="/wiki/Telimomab_aritox" title="Telimomab aritox">Telimomab aritox</a></li> <li><a href="/wiki/Vepalimomab" title="Vepalimomab">Vepalimomab</a></li> <li><a href="/wiki/Zolimomab_aritox" title="Zolimomab aritox">Zolimomab aritox</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Chimeric_antibody" class="mw-redirect" title="Chimeric antibody">Chimeric</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Andecaliximab" title="Andecaliximab">Andecaliximab</a><sup>†</sup></li> <li><a href="/wiki/Basiliximab" title="Basiliximab">Basiliximab</a></li> <li><a href="/wiki/Clenoliximab" title="Clenoliximab">Clenoliximab</a></li> <li><a href="/wiki/Galiximab" title="Galiximab">Galiximab</a></li> <li><a href="/wiki/Gomiliximab" class="mw-redirect" title="Gomiliximab">Gomiliximab</a></li> <li><a href="/wiki/Infliximab" title="Infliximab">Infliximab</a></li> <li><a href="/wiki/Keliximab" title="Keliximab">Keliximab</a></li> <li><a href="/wiki/Lumiliximab" title="Lumiliximab">Lumiliximab</a></li> <li><a href="/wiki/Priliximab" title="Priliximab">Priliximab</a></li> <li><a href="/wiki/Teneliximab" title="Teneliximab">Teneliximab</a></li> <li><a href="/wiki/Vapaliximab" title="Vapaliximab">Vapaliximab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Humanized_antibody" title="Humanized antibody">Humanized</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i>Immunosuppressive:</i> <a href="/wiki/Apolizumab" title="Apolizumab">Apolizumab</a><sup>§</sup></li> <li><a href="/wiki/Aselizumab" title="Aselizumab">Aselizumab</a></li> <li><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a></li> <li><a href="/wiki/Benralizumab" title="Benralizumab">Benralizumab</a></li> <li><a href="/wiki/Camrelizumab" title="Camrelizumab">Camrelizumab</a><sup>†</sup></li> <li><a href="/wiki/Cedelizumab" title="Cedelizumab">Cedelizumab</a></li> <li><a href="/wiki/Certolizumab_pegol" title="Certolizumab pegol">Certolizumab pegol</a></li> <li><a href="/wiki/Crizanlizumab" title="Crizanlizumab">Crizanlizumab</a></li> <li><a href="/wiki/Daclizumab" title="Daclizumab">Daclizumab</a></li> <li><a href="/wiki/Eculizumab" title="Eculizumab">Eculizumab</a></li> <li><a href="/wiki/Efalizumab" title="Efalizumab">Efalizumab</a><sup>‡</sup></li> <li><a href="/wiki/Epratuzumab" title="Epratuzumab">Epratuzumab</a></li> <li><a href="/wiki/Erlizumab" title="Erlizumab">Erlizumab</a></li> <li><a href="/wiki/Etrolizumab" title="Etrolizumab">Etrolizumab</a><sup>†</sup></li> <li><a href="/wiki/Fontolizumab" title="Fontolizumab">Fontolizumab</a></li> <li><a href="/wiki/Frexalimab" title="Frexalimab">Frexalimab</a><sup>†</sup></li> <li><a href="/wiki/Inebilizumab" title="Inebilizumab">Inebilizumab</a></li> <li><a href="/wiki/Itolizumab" title="Itolizumab">Itolizumab</a></li> <li><a href="/wiki/Lampalizumab" title="Lampalizumab">Lampalizumab</a><sup>†</sup></li> <li><a href="/wiki/Letolizumab" title="Letolizumab">Letolizumab</a></li> <li><a href="/wiki/Ligelizumab" title="Ligelizumab">Ligelizumab</a><sup>†</sup></li> <li><a href="/wiki/Lulizumab_pegol" title="Lulizumab pegol">Lulizumab pegol</a></li> <li><a href="/wiki/Mepolizumab" title="Mepolizumab">Mepolizumab</a></li> <li><a href="/wiki/Mogamulizumab" title="Mogamulizumab">Mogamulizumab</a></li> <li><a href="/wiki/Natalizumab" title="Natalizumab">Natalizumab</a></li> <li><a href="/wiki/Ocrelizumab" title="Ocrelizumab">Ocrelizumab</a> (<a href="/wiki/Ocrelizumab/hyaluronidase" title="Ocrelizumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Omalizumab" title="Omalizumab">Omalizumab</a></li> <li><a href="/wiki/Ozoralizumab" title="Ozoralizumab">Ozoralizumab</a></li> <li><a href="/wiki/Pascolizumab" title="Pascolizumab">Pascolizumab</a></li> <li><a href="/wiki/Pateclizumab" title="Pateclizumab">Pateclizumab</a></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li> <li><a href="/wiki/Pexelizumab" title="Pexelizumab">Pexelizumab</a></li> <li><a href="/wiki/Pidilizumab" title="Pidilizumab">Pidilizumab</a></li> <li><a href="/wiki/Plozalizumab" title="Plozalizumab">Plozalizumab</a></li> <li><a href="/wiki/PRO_140" class="mw-redirect" title="PRO 140">PRO 140</a><sup>†</sup></li> <li><a href="/wiki/Quilizumab" title="Quilizumab">Quilizumab</a></li> <li><a href="/wiki/Ravulizumab" title="Ravulizumab">Ravulizumab</a></li> <li><a href="/wiki/Reslizumab" title="Reslizumab">Reslizumab</a></li> <li><a href="/wiki/Retifanlimab" title="Retifanlimab">Retifanlimab</a></li> <li><a href="/wiki/Rontalizumab" title="Rontalizumab">Rontalizumab</a></li> <li><a href="/wiki/Rovelizumab" title="Rovelizumab">Rovelizumab</a></li> <li><a href="/wiki/Ruplizumab" title="Ruplizumab">Ruplizumab</a></li> <li><a href="/wiki/Samalizumab" title="Samalizumab">Samalizumab</a></li> <li><a href="/wiki/Satralizumab" title="Satralizumab">Satralizumab</a></li> <li><a href="/wiki/Siplizumab" title="Siplizumab">Siplizumab</a></li> <li><a href="/wiki/Spartalizumab" title="Spartalizumab">Spartalizumab</a><sup>†</sup></li> <li><a href="/wiki/Talizumab" title="Talizumab">Talizumab</a></li> <li><a href="/wiki/Teclistamab" title="Teclistamab">Teclistamab</a></li> <li><a href="/wiki/Teplizumab" title="Teplizumab">Teplizumab</a></li> <li><a href="/wiki/Tislelizumab" title="Tislelizumab">Tislelizumab</a></li> <li><a href="/wiki/Tocilizumab" title="Tocilizumab">Tocilizumab</a></li> <li><a href="/wiki/Toralizumab" title="Toralizumab">Toralizumab</a></li> <li><a href="/wiki/Tregalizumab" title="Tregalizumab">Tregalizumab</a></li> <li><a href="/wiki/Vatelizumab" title="Vatelizumab">Vatelizumab</a></li> <li><a href="/wiki/Vedolizumab" title="Vedolizumab">Vedolizumab</a></li> <li><a href="/wiki/Visilizumab" title="Visilizumab">Visilizumab</a></li> <li><a href="/wiki/Vobarilizumab" title="Vobarilizumab">Vobarilizumab</a></li> <li><a href="/wiki/TGN1412" class="mw-redirect" title="TGN1412">TGN1412</a><sup>§</sup><br /></li></ul> <p><i>Immune activation</i>: <a href="/wiki/Dostarlimab" title="Dostarlimab">Dostarlimab</a><br /> <i>Other:</i> <a href="/wiki/Ibalizumab" title="Ibalizumab">Ibalizumab</a> </p> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric + humanized<br /></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Otelixizumab" title="Otelixizumab">Otelixizumab</a></li> <li><a href="/wiki/Rozanolixizumab" title="Rozanolixizumab">Rozanolixizumab</a></li> <li><a href="/wiki/Sutimlimab" title="Sutimlimab">Sutimlimab</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%"><a href="/wiki/Interleukin" title="Interleukin">Interleukin</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Bermekimab" title="Bermekimab">Bermekimab</a></li> <li><a href="/wiki/Brazikumab" title="Brazikumab">Brazikumab</a></li> <li><a href="/wiki/Briakinumab" title="Briakinumab">Briakinumab</a></li> <li><a href="/wiki/Canakinumab" title="Canakinumab">Canakinumab</a></li> <li><a href="/wiki/Fezakinumab" title="Fezakinumab">Fezakinumab</a></li> <li><a href="/wiki/Fletikumab" title="Fletikumab">Fletikumab</a></li> <li><a href="/wiki/Guselkumab" title="Guselkumab">Guselkumab</a></li> <li><a href="/wiki/Secukinumab" title="Secukinumab">Secukinumab</a></li> <li><a href="/wiki/Sirukumab" title="Sirukumab">Sirukumab</a></li> <li><a href="/wiki/Tralokinumab" title="Tralokinumab">Tralokinumab</a></li> <li><a href="/wiki/Ustekinumab" title="Ustekinumab">Ustekinumab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Anrukinzumab" title="Anrukinzumab">Anrukinzumab</a></li> <li><a href="/wiki/Bimekizumab" title="Bimekizumab">Bimekizumab</a></li> <li><a href="/wiki/Clazakizumab" title="Clazakizumab">Clazakizumab</a></li> <li><a href="/wiki/Gevokizumab" title="Gevokizumab">Gevokizumab</a></li> <li><a href="/wiki/Ixekizumab" title="Ixekizumab">Ixekizumab</a></li> <li><a href="/wiki/Mirikizumab" title="Mirikizumab">Mirikizumab</a><sup>†</sup></li> <li><a href="/wiki/Lebrikizumab" title="Lebrikizumab">Lebrikizumab</a></li> <li><a href="/wiki/Olokizumab" title="Olokizumab">Olokizumab</a><sup>†</sup></li> <li><a href="/wiki/Perakizumab" title="Perakizumab">Perakizumab</a></li> <li><a href="/wiki/Risankizumab" title="Risankizumab">Risankizumab</a></li> <li><a href="/wiki/Spesolimab" title="Spesolimab">Spesolimab</a></li> <li><a href="/wiki/Tildrakizumab" title="Tildrakizumab">Tildrakizumab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Veterinary</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Lokivetmab" title="Lokivetmab">Lokivetmab</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Inflammatory <a href="/wiki/Lesion" title="Lesion">lesions</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Mouse5" scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Besilesomab" title="Besilesomab">Besilesomab</a></li> <li><a href="/wiki/Technetium_(99mTc)_fanolesomab" title="Technetium (99mTc) fanolesomab">Fanolesomab</a><sup>‡</sup></li> <li><a href="/wiki/Lemalesomab" title="Lemalesomab">Lemalesomab</a></li> <li><a href="/wiki/Technetium_(99mTc)_sulesomab" title="Technetium (99mTc) sulesomab">Sulesomab</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="text-align:center;;padding: 0px;"><div><div class="hlist"> <ul><li><sup>#</sup><a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li> <li><sup>‡</sup><a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li> <li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>: <ul><li><sup>†</sup><a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li> <li><sup>§</sup>Never to phase III</li></ul></li></ul> </div></div></td></tr></tbody></table></div> <style data-mw-deduplicate="TemplateStyles:r1130092004">.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-related{font-size:100%;justify-content:flex-start}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;flex:0 0 auto;min-height:24px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;flex:0 1 auto;padding:0.15em 0;column-gap:1em;align-items:baseline;margin:0;list-style:none}.mw-parser-output .portal-bar-content-related{margin:0;list-style:none}.mw-parser-output .portal-bar-item{display:inline-block;margin:0.15em 0.2em;min-height:24px;line-height:24px}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap;align-items:baseline}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-related{font-size:100%;align-items:flex-start}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:center;flex:0;column-gap:1em;border-top:1px solid #a2a9b1;margin:0 auto;list-style:none}.mw-parser-output .portal-bar-content-related{border-top:none;margin:0;list-style:none}}.mw-parser-output .navbox+link+.portal-bar,.mw-parser-output .navbox+style+.portal-bar,.mw-parser-output .navbox+link+.portal-bar-bordered,.mw-parser-output .navbox+style+.portal-bar-bordered,.mw-parser-output .sister-bar+link+.portal-bar,.mw-parser-output .sister-bar+style+.portal-bar,.mw-parser-output .portal-bar+.navbox-styles+.navbox,.mw-parser-output .portal-bar+.navbox-styles+.sister-bar{margin-top:-1px}</style><div class="portal-bar noprint metadata noviewer portal-bar-bordered" role="navigation" aria-label="Portals"><span class="portal-bar-header"><a href="/wiki/Wikipedia:Contents/Portals" title="Wikipedia:Contents/Portals">Portal</a>:</span><ul class="portal-bar-content"><li class="portal-bar-item"><span class="nowrap"><span typeof="mw:File"><span><img alt="icon" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/8px-WHO_Rod.svg.png" decoding="async" width="8" height="19" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/12px-WHO_Rod.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/16px-WHO_Rod.svg.png 2x" data-file-width="107" data-file-height="250" /></span></span> </span><a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine</a></li></ul></div>    </div><noscript><img src="https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?useformat=desktop&type=1x1&usesul3=0" alt="" width="1" height="1" style="border: none; position: absolute;"></noscript> <div class="printfooter" data-nosnippet="">Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Nivolumab&oldid=1269019282">https://en.wikipedia.org/w/index.php?title=Nivolumab&oldid=1269019282</a>"</div></div> <div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Antineoplastic_drugs" title="Category:Antineoplastic drugs">Antineoplastic drugs</a></li><li><a href="/wiki/Category:Drugs_developed_by_Bristol_Myers_Squibb" title="Category:Drugs developed by Bristol Myers Squibb">Drugs developed by Bristol Myers Squibb</a></li><li><a href="/wiki/Category:Monoclonal_antibodies_for_tumors" title="Category:Monoclonal antibodies for tumors">Monoclonal antibodies for tumors</a></li><li><a href="/wiki/Category:Orphan_drugs" title="Category:Orphan drugs">Orphan drugs</a></li><li><a href="/wiki/Category:World_Health_Organization_essential_medicines" title="Category:World Health Organization essential medicines">World Health Organization essential medicines</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Source_attribution" title="Category:Source attribution">Source attribution</a></li><li><a href="/wiki/Category:Articles_with_short_description" title="Category:Articles with short description">Articles with short description</a></li><li><a href="/wiki/Category:Short_description_is_different_from_Wikidata" title="Category:Short description is different from Wikidata">Short description is different from Wikidata</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_March_2024" title="Category:Use dmy dates from March 2024">Use dmy dates from March 2024</a></li><li><a href="/wiki/Category:Drugs_with_non-standard_legal_status" title="Category:Drugs with non-standard legal status">Drugs with non-standard legal status</a></li><li><a href="/wiki/Category:Chemicals_that_do_not_have_a_ChemSpider_ID_assigned" title="Category:Chemicals that do not have a ChemSpider ID assigned">Chemicals that do not have a ChemSpider ID assigned</a></li><li><a href="/wiki/Category:Articles_without_InChI_source" title="Category:Articles without InChI source">Articles without InChI source</a></li><li><a href="/wiki/Category:Articles_containing_unverified_chemical_infoboxes" title="Category:Articles containing unverified chemical infoboxes">Articles containing unverified chemical infoboxes</a></li><li><a href="/wiki/Category:Drugs_that_are_a_monoclonal_antibody" title="Category:Drugs that are a monoclonal antibody">Drugs that are a monoclonal antibody</a></li><li><a href="/wiki/Category:All_Wikipedia_articles_needing_clarification" title="Category:All Wikipedia articles needing clarification">All Wikipedia articles needing clarification</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_clarification_from_March_2025" title="Category:Wikipedia articles needing clarification from March 2025">Wikipedia articles needing clarification from March 2025</a></li><li><a href="/wiki/Category:Wikipedia_medicine_articles_ready_to_translate" title="Category:Wikipedia medicine articles ready to translate">Wikipedia medicine articles ready to translate</a></li></ul></div></div> </div> </main> </div> <div class="mw-footer-container"> <footer id="footer" class="mw-footer" > <ul id="footer-info"> <li id="footer-info-lastmod"> This page was last edited on 12 January 2025, at 16:59<span class="anonymous-show"> (UTC)</span>.</li> <li id="footer-info-copyright">Text is available under the <a href="/wiki/Wikipedia:Text_of_the_Creative_Commons_Attribution-ShareAlike_4.0_International_License" title="Wikipedia:Text of the Creative Commons Attribution-ShareAlike 4.0 International License">Creative Commons Attribution-ShareAlike 4.0 License</a>; additional terms may apply. By using this site, you agree to the <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Terms_of_Use" class="extiw" title="foundation:Special:MyLanguage/Policy:Terms of Use">Terms of Use</a> and <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy" class="extiw" title="foundation:Special:MyLanguage/Policy:Privacy policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a rel="nofollow" class="external text" href="https://wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li> </ul> <ul id="footer-places"> <li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy">Privacy policy</a></li> <li id="footer-places-about"><a href="/wiki/Wikipedia:About">About Wikipedia</a></li> <li id="footer-places-disclaimers"><a href="/wiki/Wikipedia:General_disclaimer">Disclaimers</a></li> <li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li> <li id="footer-places-wm-codeofconduct"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Universal_Code_of_Conduct">Code of Conduct</a></li> <li id="footer-places-developers"><a href="https://developer.wikimedia.org">Developers</a></li> <li id="footer-places-statslink"><a href="https://stats.wikimedia.org/#/en.wikipedia.org">Statistics</a></li> <li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Cookie_statement">Cookie statement</a></li> <li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Nivolumab&mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li> </ul> <ul id="footer-icons" class="noprint"> <li id="footer-copyrightico"><a href="https://www.wikimedia.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><picture><source media="(min-width: 500px)" srcset="/static/images/footer/wikimedia-button.svg" width="84" height="29"><img src="/static/images/footer/wikimedia.svg" width="25" height="25" alt="Wikimedia Foundation" lang="en" loading="lazy"></picture></a></li> <li id="footer-poweredbyico"><a href="https://www.mediawiki.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><picture><source media="(min-width: 500px)" srcset="/w/resources/assets/poweredby_mediawiki.svg" width="88" height="31"><img src="/w/resources/assets/mediawiki_compact.svg" alt="Powered by MediaWiki" lang="en" width="25" height="25" loading="lazy"></picture></a></li> </ul> </footer> </div> </div> </div> <div class="vector-header-container vector-sticky-header-container"> <div id="vector-sticky-header" class="vector-sticky-header"> <div class="vector-sticky-header-start"> <div class="vector-sticky-header-icon-start vector-button-flush-left vector-button-flush-right" aria-hidden="true"> <button class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-sticky-header-search-toggle" tabindex="-1" data-event-name="ui.vector-sticky-search-form.icon"><span class="vector-icon mw-ui-icon-search mw-ui-icon-wikimedia-search"></span> <span>Search</span> </button> </div> <div role="search" class="vector-search-box-vue vector-search-box-show-thumbnail vector-search-box"> <div class="vector-typeahead-search-container"> <div class="cdx-typeahead-search cdx-typeahead-search--show-thumbnail"> <form action="/w/index.php" id="vector-sticky-search-form" class="cdx-search-input cdx-search-input--has-end-button"> <div class="cdx-search-input__input-wrapper" data-search-loc="header-moved"> <div class="cdx-text-input cdx-text-input--has-start-icon"> <input class="cdx-text-input__input" type="search" name="search" placeholder="Search Wikipedia"> <span class="cdx-text-input__icon cdx-text-input__start-icon"></span> </div> <input type="hidden" name="title" value="Special:Search"> </div> <button class="cdx-button cdx-search-input__end-button">Search</button> </form> </div> </div> </div> <div class="vector-sticky-header-context-bar"> <nav aria-label="Contents" class="vector-toc-landmark"> <div id="vector-sticky-header-toc" class="vector-dropdown mw-portlet mw-portlet-sticky-header-toc vector-sticky-header-toc vector-button-flush-left" > <input type="checkbox" id="vector-sticky-header-toc-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-sticky-header-toc" class="vector-dropdown-checkbox " aria-label="Toggle the table of contents" > <label id="vector-sticky-header-toc-label" for="vector-sticky-header-toc-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-listBullet mw-ui-icon-wikimedia-listBullet"></span> <span class="vector-dropdown-label-text">Toggle the table of contents</span> </label> <div class="vector-dropdown-content"> <div id="vector-sticky-header-toc-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <div class="vector-sticky-header-context-bar-primary" aria-hidden="true" ><span class="mw-page-title-main">Nivolumab</span></div> </div> </div> <div class="vector-sticky-header-end" aria-hidden="true"> <div class="vector-sticky-header-icons"> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only" id="ca-talk-sticky-header" tabindex="-1" data-event-name="talk-sticky-header"><span class="vector-icon mw-ui-icon-speechBubbles mw-ui-icon-wikimedia-speechBubbles"></span> <span></span> </a> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only" id="ca-subject-sticky-header" tabindex="-1" data-event-name="subject-sticky-header"><span class="vector-icon mw-ui-icon-article mw-ui-icon-wikimedia-article"></span> <span></span> </a> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only" id="ca-history-sticky-header" tabindex="-1" data-event-name="history-sticky-header"><span class="vector-icon mw-ui-icon-wikimedia-history mw-ui-icon-wikimedia-wikimedia-history"></span> <span></span> </a> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only mw-watchlink" id="ca-watchstar-sticky-header" tabindex="-1" data-event-name="watch-sticky-header"><span class="vector-icon mw-ui-icon-wikimedia-star mw-ui-icon-wikimedia-wikimedia-star"></span> <span></span> </a> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only" id="ca-edit-sticky-header" tabindex="-1" data-event-name="wikitext-edit-sticky-header"><span class="vector-icon mw-ui-icon-wikimedia-wikiText mw-ui-icon-wikimedia-wikimedia-wikiText"></span> <span></span> </a> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only" id="ca-ve-edit-sticky-header" tabindex="-1" data-event-name="ve-edit-sticky-header"><span class="vector-icon mw-ui-icon-wikimedia-edit mw-ui-icon-wikimedia-wikimedia-edit"></span> <span></span> </a> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only" id="ca-viewsource-sticky-header" tabindex="-1" data-event-name="ve-edit-protected-sticky-header"><span class="vector-icon mw-ui-icon-wikimedia-editLock mw-ui-icon-wikimedia-wikimedia-editLock"></span> <span></span> </a> </div> <div class="vector-sticky-header-buttons"> <button class="cdx-button cdx-button--weight-quiet mw-interlanguage-selector" id="p-lang-btn-sticky-header" tabindex="-1" data-event-name="ui.dropdown-p-lang-btn-sticky-header"><span class="vector-icon mw-ui-icon-wikimedia-language mw-ui-icon-wikimedia-wikimedia-language"></span> <span>17 languages</span> </button> <a href="#" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--action-progressive" id="ca-addsection-sticky-header" tabindex="-1" data-event-name="addsection-sticky-header"><span class="vector-icon mw-ui-icon-speechBubbleAdd-progressive mw-ui-icon-wikimedia-speechBubbleAdd-progressive"></span> <span>Add topic</span> </a> </div> <div class="vector-sticky-header-icon-end"> <div class="vector-user-links"> </div> </div> </div> </div> </div> <div class="mw-portlet mw-portlet-dock-bottom emptyPortlet" id="p-dock-bottom"> <ul> </ul> </div> <script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgHostname":"mw-web.eqiad.main-5b7d47cbb-s42nv","wgBackendResponseTime":336,"wgPageParseReport":{"limitreport":{"cputime":"0.949","walltime":"1.160","ppvisitednodes":{"value":9088,"limit":1000000},"postexpandincludesize":{"value":307303,"limit":2097152},"templateargumentsize":{"value":15855,"limit":2097152},"expansiondepth":{"value":18,"limit":100},"expensivefunctioncount":{"value":5,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":283346,"limit":5000000},"entityaccesscount":{"value":1,"limit":400},"timingprofile":["100.00% 920.918 1 -total"," 33.93% 312.493 1 Template:Reflist"," 30.56% 281.447 1 Template:Infobox_drug"," 23.99% 220.951 1 Template:Infobox"," 16.29% 150.004 30 Template:Cite_web"," 13.15% 121.092 10 Template:Navbox"," 9.84% 90.636 1 Template:Targeted_cancer_therapeutic_agents"," 8.50% 78.254 16 Template:Cite_journal"," 6.62% 60.966 2 Template:Short_description"," 5.64% 51.915 1 Template:Chem_molar_mass"]},"scribunto":{"limitreport-timeusage":{"value":"0.472","limit":"10.000"},"limitreport-memusage":{"value":10381654,"limit":52428800}},"cachereport":{"origin":"mw-web.codfw.next-5974465d9c-vssf4","timestamp":"20250308163705","ttl":2013781,"transientcontent":true}}});});</script> <script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Nivolumab","url":"https:\/\/en.wikipedia.org\/wiki\/Nivolumab","sameAs":"http:\/\/www.wikidata.org\/entity\/Q7041828","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q7041828","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2012-03-08T19:20:00Z","dateModified":"2025-01-12T16:59:56Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/1\/1e\/Nivolumab_5GGR.png","headline":"Cancer drug, Anti PD-1 monoclonal antibody"}</script> </body> </html>